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Abstract:  
Voltage-gated sodium channels (VGSCs), composed of a pore-forming α subunit and 
up to two associated β subunits, are critical for the initiation of the action potential in 
excitable tissues. VGSC β subunits, first cloned in 1992, modulate sodium current but 
also play non-conducting roles as cell adhesion molecules that allow them to function in 
the processes of neuronal migration, neurite outgrowth, pathfinding, and axonal 
fasciculation. Mutations in VGSC α and β genes are associated with diseases caused 
by dysfunction of excitable tissues such as epilepsy. SCN1B-C121W, the first epilepsy-
associated sodium channel mutation identified, results in Genetic Epilepsy with Febrile 
Seizures plus (GEFS+). This mutation in SCN1B, which encodes the VGSC β1/1B 
subunits, disrupts sodium current modulation and cell adhesive functions of β1 in vitro. 
The goal of my thesis research was to compare mice heterozygous for Scn1b-C121W 
(Scn1b+/W) with mice heterozygous for the Scn1b null allele (Scn1b+/-) to ask whether 
the C121W mutation results in loss-of-function in vivo. I found that Scn1b+/W mice were 
more susceptible than Scn1b+/- and Scn1b+/+ mice to hyperthermia-induced seizures, a 
model for pediatric febrile seizures. Importantly, 1-C121W subunits are expressed at 
the neuronal cell surface in vivo. However, β1-C121W polypeptides are incompletely 
glycosylated and do not associate biochemically with VGSC α subunits. 1-C121W 
localization is restricted to the neuronal cell body in Scn1bW/W mice and is not detected 
at optic nerve nodes of Ranvier or axon initial segments in the cortex or cerebellum. 
These data, taken together with our previous results showing that 1-C121W cannot 
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participate in trans homophilic cell adhesion, lead to the hypothesis that SCN1B-C121W 
confers a deleterious gain-of-function. 1-C121W expression in brain may dilute the 
density of 1-WT subunits at the plasma membrane and thus effectively reduce the 
level of 1 functionality in neurons. In addition, 1-mediated trans homophilic cell-cell 
adhesion may be particularly disrupted in this mechanism, since WT-mutant or mutant-
mutant 1 subunit pairs may be aligned, but not associated, in trans on adjacent axons, 
resulting in areas of aberrant adhesion and fasciculation. 
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Chapter 1. Voltage-gated Na+ channels: Not just for 
conduction 
A version of this chapter up to the section on ”SCN1B-C121W: a GEFS+-associated 
VGSC mutation” has been accepted for publication by Cold Spring Harbor Protocols. 
Slight alterations have been added to make it more cohesive with the rest of the thesis. 
Voltage-gated sodium channels (VGSCs) conduct inward current that depolarizes the 
plasma membrane and initiates the action potential (AP) in excitable cells, including 
neurons, cardiomyocytes, and skeletal muscle cells. Because of the intrinsic link 
between VGSCs and cellular excitability, it is not surprising that mutations in VGSC 
genes are linked with epilepsy, cardiac arrhythmia, neuropathic pain, migraine, and 
neuromuscular disorders (Table 1.1). The goal of this review is to provide an overview 
of critical discoveries in VGSC physiology and discuss the challenges of studying 
VGSCs in disease, including some of the exciting techniques to address these 
challenges. Finally, I will discuss what is known about a particular mutation in a VGSC 
gene and why we decided to do the studies presented in this thesis. 
VGSC Discovery and Structure 
In 1952, the Nobel Laureates Professor Alan Lloyd Hodgkin and Professor Andrew 
Fielding Huxley first recorded sodium current (INa) using their voltage-clamp technique 
on the squid giant axon. Their experiments showed three key features of INa: selective 
Na+ conductance, voltage-dependent activation, and rapid inactivation (Hodgkin and 
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Huxley, 1952). The Hodgkin-Huxley model mathematically described voltage-dependent 
initiation of the AP by inward INa, followed by fast inactivation of INa, and simultaneous 
activation of outward IK. Outward IK was postulated to re-establish the charge balance 
across the plasma membrane (Hodgkin and Huxley, 1952). These results were 
supported by studies of peripheral motor neurons by Sir John Carew Eccles, who 
shared the Nobel Prize with Hodgkin and Huxley. Among other contributions, he 
identified deviations in membrane potential and APs due to injections of sodium into 
motor neurons (Coombs et al., 1955). In addition to this monumental discovery, 
refinement of the voltage-clamp technique opened the door for a plethora of research 
on membrane potential physiology.  
In the 1960s, Dr. Bertil Hille and Dr. Clay Armstrong proposed the idea that INa and IK 
are conducted through specific ion channels. At that time, many studies centered on 
performing voltage-clamp recordings of squid axon with sodium-free solutions 
containing organic cations (e.g. ammonium) to determine the size of the ion-conducting 
pore. The axon membrane became transiently permeable to these ions following 
depolarization, and this permeability was abolished by tetrodotoxin (TTX) (Larramendi 
et al., 1956; Lorente De No et al., 1957; Tasaki et al., 1965, 1966; Tasaki and Singer, 
1966; Binstock and Lecar, 1969). Dr. Hille added to this body of work by using 
additional metal and many organic cations to develop a model of the narrowest region 
of the ion-conducting pore of the channel (Hille, 1971, 1972). Dr. Hille’s model proposed 
a partial dehydration of Na+ through interaction with a high-field-strength site at the 
extracellular end of the pore followed by rehydration in the lumen of the pore. This 
model is astonishingly close to what we now know to be true about VGSCs from crystal 
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Table 1.1 Tissue distribution and disease associations of VGSC genes 
Gene 
symbol 
Type Tissue distribution Consequence of mutations TTX 
sensitivity 
SCN1A Nav1.1 CNS, PNS, heart, DRG DS, Familial Autism, FHM3, 
FS+, GEFS+, SUDEP 
+ 
SCN2A Nav1.2 CNS, PNS, DRG BFNIS, DS, EOEE, Familial 
Autism, GEFS, OS 
+ 
SCN3A Nav1.3 CNS, PNS, heart, DRG Unclear + 
SCN4A Nav1.4 Skeletal muscle, heart, DRG PAM, PMC, HyperPP, 
HypoPP, SNEL 
+ 
SCN5A Nav1.5 Skeletal muscle, heart, CNS, 
DRG 
AF, AS, BS, DCM, LQTS, 
PCCD, SIDS, SSS, SUDEP 
- 
SCN8A Nav1.6 CNS, PNS, heart, DRG EOEE; cognitive impairment, 
paralysis, ataxia, dystonia 
+ 
SCN9A Nav1.7 DRG CIP, IEM, PEPD, PPN + 
SCN10A Nav1.8 DRG PPN - 
SCN11A Nav1.9 DRG PPN - 
SCN1B β1 CNS, PNS, heart, DRG, glia 
(oligodendrocytes, Schwann cells, 
astrocytes, radial glia) 
AF, BS, DS, GEFS+, LQTS, 
PCCD, TLE 
N/A 
SCN2B β2 CNS, PNS, heart, DRG AF, BS N/A 
SCN3B β3 CNS, PNS, heart, DRG AF, BS, PCCD, SIDS, 
ventricular fibrillation 
N/A 
SCN4B β4 CNS, PNS, heart, DRG LQTS, SIDS N/A 
SCN1B β1B Fetal CNS, PNS, heart, DRG BS, PCCD, epilepsy N/A 
AF, atrial fibrillation; AS, atrial standstill; BFNIS, benign familial neonatal-infantile seizures; BS, 
brugada syndrome; CIP, channelopathy-associated insensitivity to pain; CNS, central nervous system; 
DCM, dilated cardiomyopathy; DRG, dorsal root ganglia; DS, Dravet Syndrome; EOEE, early-onset 
epileptic encephalopathy; FHM3, familial hemiplegic migraine type 3; FS+, febrile seizures plus; 
GEFS+, genetic epilepsy with febrile seizures plus; HyperPP, hyperkalemic periodic paralysis, 
HypoPP, hypokalemic periodic paralysis; IEM, inherited erythromelaglia; LQTS, long QT syndrome; 
OS, Ohtahara syndrome; PAM, potassium-aggravated myotonia; PCCD, progressive cardiac 
conduction disease; PEPD, paroxysmal extreme pain disorder formally known as familial rectal pain 
syndrome; PMC, Paramyotonia congenital; PNS, peripheral nervous system; PPN, painful peripheral 
neuropathies; SIDS, sudden infant death syndrome; SNEL, severe neonatal episodic laryngospasm; 
SSS, sick sinus syndrome; SUDEP, sudden unexplained death in epilepsy; TLE, temporal lobe 
epilepsy 
Modified with permission from Patino and Isom 2010, copyright Elsevier Ireland Ltd; Catterall 2012, 
copyright Wiley Company; Brunklaus et al. 2014, copyright BMJ Publishing Group Ltd. 
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structure information (Payandeh et al., 2011; McCusker et al., 2012; Zhang et al., 2012). 
Dr. Armstrong and Dr. Francisco Bezanilla developed signal averaging techniques to 
detect the movement of ‘gating charges’ (Armstrong and Bezanilla, 1973, 1974) 
corresponding to what we now understand to be the movement of voltage sensors, 
which respond to changes in membrane potential. Remarkably, without having any of 
the knowledge that we possess today about nucleotide/amino acid sequence and 
crystal structures, these early studies made many accurate predictions about VGSC 
structure and the functions of various channel domains. 
While early physiological studies provided evidence for the existence of a VGSC, the 
biochemical proof that tetrodotoxin/saxitoxin (STX) receptors were also ion-conducting 
did not yet exist. Membrane protein purification techniques were being established, but 
they required an extraordinarily large amount of time and biological starting material 
compared to today’s techniques. Photoaffinity labeling of STX receptors with a scorpion 
toxin derivative by Dr. William Catterall’s group identified a family of VGSC proteins that 
were designated α and β subunits (Beneski and Catterall, 1980). Purification of VGSC 
protein to theoretical homogeneity was challenging due to the difficulty of solubilizing a 
high molecular weight, highly lipophilic membrane protein and the large amount of 
biological starting material required. Again, the Catterall lab was the first to overcome 
these challenges and purify VGSCs from rat brain (Hartshorne and Catterall, 1981, 
1984; Hartshorne et al., 1982). This work was closely followed by purification of VGSCs 
from rat and rabbit skeletal muscle (Barchi, 1983; Kraner et al., 1985), and from chicken 
heart (Lombet and Lazdunski, 1984). Reconstitution of purified VGSCs in a lipid bilayer 
membrane allowed observation of Na+ flux and confirmed that a functional VGSC 
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protein had been purified (Hartshorne et al., 1985). The evolution of VGSC purification 
methods is discussed in detail in (Catterall, 1992). Purification from rat brain revealed 
that VGSCs are heterotrimers, composed of a single α subunit and two non-pore-
forming β subunits, β1 and β2 (Hartshorne and Catterall, 1981). We now know that 
there are more than two VGSC β subunits. Subsequent homology cloning and 
heterologous expression studies showed that each VGSC α is associated at the plasma 
membrane with a non-covalently linked β1 or β3 subunit and a covalently linked β2 or 
β4 subunit (Morgan et al., 2000; Yu et al., 2003).  
To clone the first VGSC α subunit cDNA, researchers from Dr. Shosaku Numa’s group 
took on the arduous task of purifying brain VGSCs and obtaining partial amino acid 
sequence by N-terminal Edman degradation as well as through cleaved peptides from 
the  subunit. They then generated and screened multiple cDNA libraries based first on 
predicted degenerate cDNA sequences and then on cloned sequences. Assembly of 
the cloned VGSC cDNA fragments revealed what we now know to be Scn1a (Noda et 
al., 1984). Heterologous expression of the cloned cDNAs gave a functional channel, 
which we now recognize as Nav1.1.  
VGSC β subunits are required to recapitulate physiological 
expression of INa in Xenopus oocytes 
Early cloning of Nav1.2 cDNA and its expression in oocytes resulted in INa that 
inactivated more slowly than INa recorded from neurons. Co-injection of low-molecular 
weight rat brain mRNA was required for recapitulation of physiological INa in terms of 
rates of activation and inactivation, and voltage dependence (Auld et al., 1988; Krafte, 
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1990). Cloning and expression of the VGSC β1 and β2 subunits showed that they 
mimicked the effects of low molecular weight mRNA on  subunit expression in oocytes 
(Isom et al., 1992, 1995b). Co-expression of Nav1.2 + 1 in oocytes resulted in a larger 
INa that activated and inactivated more rapidly and had a negative shift in the voltage-
dependence of inactivation compared to  alone. Co-expression of Nav1.2 with both β1 
and β2 further increased INa density (Isom et al., 1995b). As discussed by Calhoun and 
Isom, when expressed in heterologous systems, β subunits in general increase INa 
density, shift the voltage-dependence of current activation and inactivation, and 
accelerate the rates of activation and inactivation. However, the magnitude of current 
increase and direction of the shifts in activation and inactivation are dependent upon the 
particular heterologous cell line and the identities of the β and α cDNAs expressed 
(Calhoun and Isom, 2014). Importantly, heterologous expression systems cannot 
replicate the native cellular milieu, especially the multi-protein VGSC complexes that are 
known to form in specific subcellular domains of neurons and cardiac myocytes 
(Calhoun and Isom, 2014). For example, in Scn1b null ventricular myocytes, peak and 
persistent sodium current is increased, mediated by increased Nav1.5 expression, with 
no effect on channel kinetics and voltage dependence (Lopez-Santiago et al., 2007). 
Furthermore, loss of Scn1b also results in increased TTX-S current and Scn3a 
expression in ventricular myocytes (Lin et al., 2015). However, in the dorsal root 
ganglia, critical neurons for peripheral pain sensation, Scn1b deletion causes a 
depolarizing shift in the voltage dependence of VGSC inactivation and decreased 
persistent INa+ (Lopez-Santiago et al., 2011). As heterologous expression systems 
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cannot accurately replicate these cell types, in vivo and transgenic mouse models offer 
more appropriate methods for studying the functional roles of VGSC subunits. 
Mechanistic Insights on VGSC Structure and Function 
VGSC α subunits are highly evolutionarily conserved. Each  subunit is composed of 4 
homologous domains, each containing six transmembrane helices (S1-S6), which come 
together in pseudo-tetrafold symmetry to form the ion-conducting pore (Figure 1.1). As 
discussed earlier, long before the emergence of crystal structures, much of VGSC 
structure and function was inferred through studies modeling gating and using site-
specific antibodies and toxins during electrophysiological recordings.  
The sliding-helix model of VGSC voltage-dependent activation was proposed in the 
1980’s by Dr. Catterall (Catterall, 1986a,b). The S4 segments of each domain, which 
serve as voltage sensors, contain arginine residues at every third position, which pair 
with negatively charged residues in nearby transmembrane segments. Upon membrane 
depolarization, these residues change ion-pair partners, causing each S4 helix to rotate 
or slide outward, pushing a single arginine residue in each of the four segments out, 
and generating gating current that activates, or opens, the channel pore (Payandeh et 
al., 2011). Data from potassium channel structures prompted the paddle model as an 
alternate mechanism of voltage-dependent activation (Jiang et al., 2003), however, the 
solving of multiple prokaryotic α subunit crystal structures demonstrated the validity of 
the sliding helix model for VGSCs (Payandeh et al., 2011; Vargas et al., 2012).
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Figure 1.1 VGSC α and β subunit topology. 
The pore-forming α subunit is composed of four homologous domains (I-IV), each with 
six transmembrane segments. The fourth segment in each domain contains the voltage-
sensing domain of the channel. The inactivation loop between domains III and IV 
contains the IFM domain required for channel inactivation. Up to two β subunits may be 
associated with VGSCs. β1 and β3 subunits associate non-covalently, while β2 and β4 
subunits associate via a disulfide link. Reprinted with permission from Brackenbury and 
Isom, 2011, copyright Frontiers Media SD
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Another critical property of VGSCs is voltage-dependent inactivation, which occurs in 
spite of an on-going depolarizing pulse. Early studies identified the intracellular loop 
between domains III and IV as the inactivation gate (Figure 1.1). This was proposed to 
“swing” into the pore in a voltage-dependent manner, physically blocking ion 
conduction, and effectively inactivating the pore (Vassilev et al., 1988, 1989). A short 
amino acid sequence in the inactivation gate, IFM, was identified as critical to the 
process of inactivation. Mutation of these three residues to glutamine resulted in a non-
inactivating channel (West et al., 1992; Kellenberger, 1997). These studies, combined 
with a three-dimensional NMR structure of the inactivation gate (Rohl et al., 1999), 
helped form the current understanding of the molecular basis for fast inactivation of 
VGSCs. 
Recent crystal structures of bacterial VGSCs have led to a more detailed understanding 
of the pore and selectivity filter. The membrane re-entrant P-loop, located between 
transmembrane helices S5 and S6 of each domain that line the pore, was identified as 
the target for the pore-blocking TTX, suggesting its close location to the pore (Noda et 
al., 1989; Terlau et al., 1991). The crystal structure of a bacterial VGSC showed that the 
4 P-loops together form a ring of glutamates, located near the extracellular end of the 
pore (Payandeh et al., 2011). As predicted in 1992, these highly-conserved glutamates 
form a high-field-strength site critical in determining ion selectivity of the channel 
(Heinemann et al., 1992). These residues stabilize multiple ionic occupancy states, 
preferentially conducting hydrated Na+ through the pore (Payandeh et al., 2011). In 
contrast, potassium channels conduct dehydrated K+ (Doyle et al., 1998).  
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Capturing crystal structures of bacterial VGSCs in different activation states has 
provided new insights and biochemical modeling tools. A closed-pore conformation of 
the Arcobacter channel (NavAb), crystallized within a lipid-based bicelle, offered the first 
VGSC 3D structure (Payandeh et al., 2011). A putatively inactive NavRh channel from 
the marine bacterium Rickettsiales showed significant differences from NavAb and 
supplied new information about conformational rearrangements required for inactivation 
(Zhang et al., 2012). Finally, the apparently open conformation of the NavM structure 
from the marine bacterium Magnetococcus presented further insights into channel 
gating and selectivity (McCusker et al., 2012). 
Despite the wealth of information provided by these prokaryotic VGSC structures, 
crystallization of a eukaryotic VGSC is the essential next step. While prokaryotic VGSCs 
are homotetramers, mammalian VGSC  subunits are single polypeptides containing 4 
non-identical domains. Further, the extensive extracellular and intracellular loops of 
mammalian channels are not present in their prokaryotic orthologs. Thus, major gaps in 
the field include the crystal structure of a mammalian  subunit and the co-crystal 
structure of an  subunit associated with β subunits. This information will be critical in 
fully understanding mammalian VGSC structure. 
VGSC Diversity  
Originally, VGSC  subunit proteins were named according to the tissue from which 
they were purified. For example, brain type II, rat II, and R-II are all outdated terms for 
Nav1.2 (Catterall et al., 2005). To date, nine VGSC  α proteins (Nav1.1-1.9) and five β 
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proteins (β1-4 and β1B), encoded by SCN(X)A and SCN1B-SCN4B genes, respectively, 
have been identified in mammalian genomes. 
A BLAST search of the cDNAs encoding β1 and β2 in 1995 revealed important, and 
unexpected, new information.  Both proteins contained areas of homology to known cell 
adhesion molecules (CAMs) of the immunoglobulin (Ig) superfamily, e.g. contactin and 
myelin P0. This led to the hypothesis that β1 and β2 function as CAMs in addition to 
channel modulators (Isom et al., 1995b). We now know that all five β subunit proteins 
contain an extracellular Ig domain and have CAM function, as discussed later in this 
review. β1-4 (encoded by SCN1B-SCN4B) are type 1 transmembrane proteins with an 
extracellular N-terminus (containing the Ig domain) and an intracellular C-terminus 
(Isom et al., 1992, 1995b; Morgan et al., 2000). By contrast β1B, a splice variant of 
SCN1B, is secreted. Retention of intron 3 results in generation of an alternate C-
terminal domain that does not contain a transmembrane region (Patino et al., 2011). 
Recently, the three-dimensional crystal structures of the human Ig domains of β3 and 
β4 were solved. β3 formed a trimer when crystalized (Namadurai et al., 2014). In 
contrast, the β4 Ig domain was monomeric in crystal form (Gilchrist et al., 2013). While 
this could represent a physiological difference in homophilic interactions, it could also be 
due to removal of 31 amino acids at the β4 N-terminus to facilitate crystallization 
(Gilchrist et al., 2013). Comparisons of these structures will give new insights into the 
function of β subunits, but the co-crystal structure of α and β subunits remains the next 
frontier. 
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VGSC α- and β-subunits are highly expressed in central and peripheral neurons, 
cardiac myocytes, skeletal muscle, and some non-excitable cells (Maier et al., 2004; 
Patino and Isom, 2010; Brunklaus et al., 2014), including breast cancer cells (Fraser et 
al., 2005), astrocytes, and oligodendrocytes. Adapted from (Patino and Isom, 2010; 
Catterall, 2012; Brunklaus et al., 2014), Table 1.1 shows the gene name, known tissue 
expression, and diseases associated with mutations for each VGSC subunit. VGSC 
expression is developmentally regulated. For example, Nav1.3, β3, and β1B are most 
prevalent in embryonic and neonatal rodent brain. This expression profile then changes 
such that Nav1.1, Nav1.2, Nav1.6, β1, β2, and β4 are predominant in the adult brain, 
albeit distribution is not equivalent across brain regions (Kazen-Gillespie et al., 2000; 
Catterall et al., 2005; Patino et al., 2011).  
VGSC subcellular localization is critical for normal physiological functions. In neurons, 
VGSCs are concentrated at the axon initial segment (AIS), where the AP is initiated, 
and nodes of Ranvier in myelinated axons, which are critical for saltatory conduction. In 
cardiomyocytes, VGSCs are differentially localized at intercalated disks and transverse 
tubules. Reviews that discuss this in more detail include (Bao and Isom, 2014; Calhoun 
and Isom, 2014). 
Despite their high sequence similarity, each VGSC α subunit has subtle differences in 
biophysical properties and pharmacological sensitivities, as summarized in (Catterall et 
al., 2005; Kwong and Carr, 2015). Many of the agents that target α subunits are toxins, 
including TTX, STX, μ-conotoxins, and their derivatives such as 4,9-anhydro-TTX which 
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preferentially blocks Nav1.6 (Rosker et al., 2007; Kwong and Carr, 2015). VGSCs are 
canonically separated into TTX-sensitive (TTX-S) and TTX-resistant categories (TTX-
R), which are blocked by nanomolar or micromolar concentrations of TTX, respectively 
(Catterall et al., 2005). Interestingly, mutation of a single residue changes TTX 
sensitivity (Noda et al., 1989). Modulation of INa by these toxins [reviewed by (Gilchrist 
et al., 2014)] can be affected by β subunit expression. For example, expression of β1 
and β3, but not β2 or β4, tend to increase the rate of association and binding affinity of 
μ-conotoxins for VGSCs. However, modulation of INa by STX or TTX was unaffected by 
β subunit expression (Isom et al., 1995a; Zhang et al., 2013). In vivo, a combination of 
electrophysiology and toxicology are used to infer which VGSCs contribute to aspects of 
endogenous INa. Although challenging, in vivo studies are crucial, as heterologous 
results can be difficult to translate to in vivo physiological and pathophysiological 
mechanisms.  
Postranslational Modifications of α and β subunits 
VGSC α subunits are heavily glycosylated, although the extent of glycosylation varies 
between subunits (Bennett, 2002). 40-50% of these added carbohydrate residues are 
sialic acid moieties such that each channel contains approximately100 sialic acid 
residues (Miller et al., 1983; Roberts and Barchi, 1987). Differential glycosylation of 
VGSC subunits can affect channel gating, putatively due to the local negative charge of 
sialic acid residues. In general, when α subunits are less glycosylated, channel gating 
occurs at more depolarized voltages (Recio-Pinto et al., 1990; Bennett et al., 1997; 
Zhang et al., 1999; Tyrrell et al., 2001). For example, Nav1.9 expressed in neonatal 
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dorsal root ganglia (DRG) neurons is more glycosylated than in adult DRG, suggesting 
developmental regulation of glycosylation. This may account for developmental 
differences in gating of persistent INa attributed to Nav1.9 (Tyrrell et al., 2001). Voltage-
dependent activation and inactivation of Nav1.4, but not Nav1.5, shifts when expressed 
in cells incapable of sialylation, indicating not all VGSCs are affected equally (Bennett, 
2002). Glycosylation accounts for about one-third of the molecular weights of β subunits. 
Mature β subunits contain three to four N-linked glycosylation sites in the Ig domain 
(Isom et al., 1992; McCormick et al., 1998) all of which are exposed in the β3 crystal 
structure (Namadurai et al., 2014). Sialic acid residues in these sites affect β1- and β2-
mediated modulation of INa and channel surface expression (Johnson et al., 2004; 
Johnson and Bennett, 2006). Critically, VGSC glycosylation varies developmentally and 
between cell types; e.g., neonatal and adult myocytes have distinct differences in 
glycogen expression, as do atrial and ventricular myocytes (Stocker and Bennett, 2006). 
Therefore, tissue-specific variations in β subunit processing likely include altered 
sialylation/glycosylation and may contribute to differential modulation of INa by β subunits 
between cell types (Zhang et al., 1999; Bennett, 2002).  
β1 can be phosphorylated on intracellular tyrosine residue (Y) 181 (Malhotra et al., 
2002, 2004). Tyrosine phosphorylation regulates β1-mediated recruitment of ankyrin to 
points of cell-cell contact (Malhotra et al., 2002) and likely occurs via fyn kinase, a src 
family kinase (Brackenbury et al., 2008; Nelson et al., 2014). Receptor tyrosine 
phosphatase β interacts with the intracellular domain of β1 and may modulate β1 
phosphorylation (Ratcliffe et al., 2000). In cardiac myocytes, non-phosphorylated β1 
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localizes at the t-tubules with ankyrinB while phosphorylated β1 localizes at intercalated 
disks with connexin-43, N-cadherin, and Nav1.5 (Malhotra et al., 2004). Therefore, the 
phosphorylation state Y-181 regulates β1 association with cytoskeletal proteins, as well 
as its subcellular localization. 
β subunits are substrates for sequential proteolytic cleavage by BACE1 (β-secretase) 
and γ-secretase, similar to amyloid precursor protein. BACE1 cleavage releases the 
extracellular domain (ECD), followed by a γ-secretase-mediated cleavage event to 
release the C-terminal fragment (CTF) (Wong et al., 2005). These cleaved peptides 
may have important physiological functions. For example, the β2-CTF translocates to 
the nucleus and promotes Scn1a mRNA and protein expression when heterologously 
expressed in cultured neurons (Kim et al., 2005, 2007). Consistent with this proposed 
mechanism, total and surface expression of Nav1.1 in acutely dissociated hippocampal 
neurons is significantly reduced in BACE1 null mice compared to wildtype (Kim et al., 
2011). The physiological importance of BACE1 and γ-secretase cleavage of the other β 
subunits is not understood. As β1B can act as a CAM, it is possible that the β1-ECD, 
which contains the identical Ig loop domain, functions as a ligand for cell adhesion 
(Patino et al., 2011). γ-secretase activity, and thus formation of the β1-CTF, is critical for 
β1-mediated neurite outgrowth in vitro (Brackenbury and Isom, 2011). Determining 
whether these functions occur in vivo represents a critical next step in our 
understanding of post-translational processing of VGSCs. 
16 
 
β subunits are multifunctional 
Effects on surface expression 
Co-expression of β subunits with α results in increased INa density, in part due to 
promotion of α cell surface expression. Following post-translational processing, α 
subunits are stored in an intracellular pool associated with the plasma membrane 
(Schmidt et al., 1985; Schmidt and Catterall, 1986). Concomitant with plasma 
membrane insertion, α and β2 covalently associate via a disulfide bond (Chen et al., 
2012). Scn2b null mice on the C57BL/6 x 129SV background have a 50% reduction in 
hippocampal INa density and level of surface α subunits (Chen et al., 2002). However, a 
second study of Scn2b null mice congenic on the  C57BL/6 background saw no change 
in hippocampal INa (Uebachs et al., 2010), suggesting genetic background influences on 
β2 function. The effect of β2 on channel surface expression may also depend on the 
particular α subunit. Scn2b null small-fast DRG neurons have reduced TTX-S INa, but 
unchanged TTX-R INa (Lopez-Santiago et al., 2006). A Scn2b-linked Brugada syndrome 
mutation results in decreased surface Nav1.5 protein compared to WT (Riuró et al., 
2013). Thus, modulation of α subunit surface expression by β2 may contribute to 
disease mechanisms. This is not unique to β2; β1 and β1B also promote VGSC surface 
expression [reviewed in (Calhoun and Isom, 2014)]. 
Effects of β4 on resurgent INa 
Resurgent INa is the transient opening of VGSCs during recovery from inactivation 
following the AP. This specialized current is an important adaptation for high-frequency 
firing neurons, such as cerebellar Purkinje neurons (Raman and Bean, 1997). For this 
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to occur, a ‘blocking protein,’ putatively the ICD of β4, must bind to open channels 
during depolarization and unbind upon repolarization, shortening the typical refractory 
period and producing a resurgent INa. Without β4 expression, resurgent current is lost 
from cerebellar Purkinje neurons, but is rescued by a β4 ICD peptide (Grieco et al., 
2005). This same β4 peptide is sufficient to invoke resurgent INa in Nav1.7-expressing 
HEK cells (Theile and Cummins, 2011). With β4 knockdown in cerebellar granule 
neurons, resurgent INa is decreased, but is rescued by the β4 peptide (Bant and Raman, 
2010). Other β subunits may also contribute to modulation of resurgent INa, as Scn1b 
null cerebellar granule neurons have reduced resurgent INa (Brackenbury et al., 2010).  
Cell adhesion and neurite outgrowth 
β subunits are multifunctional. They play critical roles in neurite outgrowth, migration, 
and maintenance of nodes of Ranvier. β subunits are CAMs and, as such, recruit other 
signaling proteins to the VGSC complex. Most is known about the CAM interactions of 
β1 and β2, which participate in trans-homophilic adhesion, via the Ig loop, with β1 or β2 
molecules on adjacent cells (Malhotra et al., 2000). β1 or β2 trans-homophilic adhesion 
recruits the cytoskeletal protein ankyrin to points of cell-cell contact (Malhotra et al., 
2000). Ankyrin recruitment is abolished by phosphorylation of β1-Y181 (Malhotra et al., 
2002). β1-β1 trans-homophilic adhesion promotes neurite outgrowth via a pathway 
requiring fyn kinase, the CAM contactin, γ-secretase activity, and localized INa 
(Brackenbury et al., 2008, 2010; Brackenbury and Isom, 2011). Because β1B contains 
the identical Ig loop, it similarly promotes neurite outgrowth of neurons expressing β1 
(Patino et al., 2011). Together, these properties may contribute to neuronal 
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development in vivo; Scn1b null mice have neuronal pathfinding dysfunction and 
differences in subcellular localization of α subunits at axon initial segments (Chen et al., 
2004; Brackenbury et al., 2008).  
β1, and likely β1B, interacts with other CAMs and extracellular matrix proteins, including 
contactin, neurofascin-186, NrCAM, N-cadherin, and tenascin-R (Ratcliffe et al., 2001; 
Kazarinova-Noyes et al., 2001; Malhotra et al., 2004; McEwen and Isom, 2004; Patino 
et al., 2011). Some of these interactions affect β1-modulation of α surface expression. 
For instance, coexpression of NF186 or contactin with Nav1.2 and β1 increases Nav1.2 
surface expression compared to Nav1.2 and β1 alone, although NF186 and contactin 
have no impact on Nav1.2 expression in the absence of β1 (Kazarinova-Noyes et al., 
2001; McEwen and Isom, 2004). Heterophilic interactions with tenascin-R, an 
extracellular matrix protein secreted by oligodendrocytes during myelination, repels cells 
expressing β1 or β2 and therefore may play a role in restricting VGSCs to nodes of 
Ranvier in myelinated axons (Xiao et al., 1999). The cell adhesive properties of β1 and 
β1B have likely clinical relevance, as most known SCN1B epilepsy mutations are 
located in or near the Ig loop domain [reviewed in (O’Malley and Isom, 2015)]. 
Much less is known about the CAM functions of β3 and β4. Studies of β3 homophilic 
adhesion give conflicting results: the β3 Ig domain appears to interact with full-length β3 
when expressed heterologously (Yereddi et al., 2013), yet another group reported that 
β3 expression could not induce aggregation of Drosophila S2 cells, unlike β1 and β2 
(McEwen et al., 2009). β3 and β1 likely do not associate, as β3 does not interact with a 
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peptide containing the β1-ECD (McEwen and Isom, 2004). β4 did not promote neurite 
outgrowth of cerebellar granule neurons, but this observation does not preclude other 
CAM interactions (Davis et al., 2004).  
Pathophysiological Roles of VGSCs 
Mutations in VGSC genes are associated with many types of genetic epilepsy, 
peripheral neuropathy, long QT syndrome, neuromuscular disorders, and other 
diseases associated with dysfunction of excitable tissues. Recent reviews discuss the 
complex pathophysiological mechanisms of sodium channelopathies associated with 
pain and cardiac disease (Dib-Hajj et al., 2010; Adsit et al., 2013; Bao and Isom, 2014; 
O’Malley and Isom, 2015). Here, we will focus on the role of VGSCs in the genetic 
epilepsies and cancer as examples of disease resulting from aberrant or loss of VGSC 
function in mammals. 
Epilepsy 
Epilepsy results from an imbalance between excitation and inhibition in the brain. Over 
2 million Americans have epilepsy, which can be caused by genetic mutations or brain 
injury (Hirtz et al., 2007). Epilepsy significantly impacts the quality of life for both 
patients and caregivers due to the unpredictability of seizures and the risk of co-
morbidities including cognitive decline, intellectual disability, developmental delay, and 
Sudden Unexpected Death in Epilepsy (SUDEP).  
Mutations in genes encoding VGSC  and  subunits are associated with epilepsies 
with a wide range of phenotypic severities, including genetic epilepsy with febrile 
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seizures plus (GEFS+), an inherited epilepsy with a wide range of phenotypes, and 
Dravet Syndrome (DS), one of the most devastating pediatric epileptic 
encephalopathies. An intriguing discussion of the complex mechanisms underlying DS 
was published recently (Chopra and Isom, 2014). In 1998, the first VGSC mutation 
associated with epilepsy was identified in SCN1B in a patient with GEFS+. This initial 
mutation, SCN1B-C121W, is the focus of this thesis and is discussed in further detail 
later. However, GEFS+ is incompletely penetrant and family members with the same 
SCN1B mutation presented with a wide range of epilepsy severities (Wallace et al., 
1998), a now familiar characteristic of the genetic epilepsies. Since this initial discovery, 
a large number of mutations in SCN1A, SCN2A, SCN8A, and SCN1B (Escayg et al., 
2000; O’Malley and Isom, 2015) have been implicated in multiple types of epilepsy (see 
Table 1.1, reviewed in part by (Shi et al., 2012; Steinlein, 2014; Wagnon and Meisler, 
2015)). Over 1200 mutations have been identified in SCN1A alone (Meng et al., 2015). 
Identifying the pathophysiological mechanisms underlying DS is of particular 
importance, as traditional antiepileptic drugs (AEDs) often aggravate seizures in DS 
patients and development of new therapeutics to help these patients is especially 
critical. While 70-80% of DS patients have an identified heterozygous de novo SCN1A 
mutation (Marini et al., 2011), homozygous mutations in SCN1B have been also been 
reported (Patino et al., 2009; Ogiwara et al., 2012). 
Studies of DS SCN1A mutations have shown that a majority result in loss-of-function 
(Meng et al., 2015). Studies of Scn1a+/- null mice and knockin mice expressing human 
mutations have led to the “interneuron hypothesis,” suggesting that selective INa loss in 
GABAergic interneurons causes epilepsy via loss of inhibitory tone (Yu et al., 2006). 
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However, this has become controversial (Chopra and Isom, 2014; Isom, 2014). More 
recent studies of DS patient derived induced pluripotent stem cell (iPSC) neurons 
showed either that both inhibitory and excitatory (Liu et al., 2013) or excitatory neurons 
(Jiao et al., 2013) are hyperexcitable compared to non-epileptic controls. These studies 
suggest that SCN1A haploinsufficiency may result in compensatory upregulation of 
other VGSC α subunits. Adding further complexity, Scn1a+/- mice show strain-
dependent seizure severity and survival. On the 129S6/SvEvTac background, Scn1a+/- 
mice have a mild phenotype and normal survival. In contrast, Scn1a+/- F1 generation 
C57BL/6J x 129 mice have severe epilepsy and premature lethality (Mistry et al., 2014). 
Acutely dissociated hippocampal GABAergic interneurons from F1.Scn1a+/- mice 
showed decreased INa compared to 129.Scn1a+/- and wild-type mice. However both 
129.Scn1a+/- and F1.Scn1a+/- mice showed increased INa in hippocampal pyramidal 
neurons (Mistry et al., 2014). It is postulated that 129.Scn1a+/- mice may have a milder 
phenotype due to preservation of GABAergic interneuron excitability. Hyperexcitability 
of both inhibitory and excitatory neurons may lead to seizures in DS via increased 
network excitability or synchronization of firing.  
Scn1b null mice also model DS; they experience spontaneous seizures and early 
lethality. At least one DS SCN1B mutation causes β1 to be retained intracellularly, 
preventing surface expression and thus function (Patino et al., 2009). Scn1b null mice 
have differences in neuronal pathfinding that are observed prior to seizure onset 
(Brackenbury et al., 2013). Thus, SCN1B-liked DS mutations may alter neuronal 
excitability by affecting α-subunit surface expression/function as well as by altering 
neuronal development via changes in cell adhesion.  
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A major concern for epilepsy patients and their families is the risk of SUDEP. Research 
suggests that a “perfect storm” of seizures, cardiac arrhythmias, respiratory dysfunction, 
or autonomic dysfunction contributes to SUDEP (Kalume, 2013; Massey et al., 
2014)(Auerbach et al., 2013). Heterozygous Scn1a-R1407X knock-in GEFS+/DS mice, 
as well as Scn1b null DS mice, have increased transient and persistent INa in cardiac 
myocytes, which may provide substrates for cardiac arrhythmias and contribute to 
SUDEP (Lopez-Santiago et al., 2007; Auerbach et al., 2013). Fully understanding the 
mechanisms underlying SUDEP will be essential to epilepsy treatment. 
One of the greatest challenges in epilepsy research is the need for novel AEDs. Even 
with optimal treatment, 20-30% of all epilepsy patients are pharmacoresistant, defined 
as being unresponsive to at least two different, tolerated AEDs (Kwan et al., 2010, 
2011). Even in non-refractory patients, AEDs treat disease symptoms rather than 
preventing disease progression and often have intolerable side effects. A major goal of 
studying epilepsy-associated VGSC mutations is to further understand epileptogenesis 
(how a brain becomes epileptic) to inform new AED discovery. 
Emerging roles for VGSCs in cancer 
An exciting area of research is the role of VGSCs in non-excitable cells, including 
multiple cancer cell types. Almost two decades ago, researchers observed that cancer 
cell lines with higher VGSC expression have increased cell motility and metastatic 
potential. Furthermore, the invasive capacity of these cells could be reduced by 
incubation with TTX (Grimes et al., 1995; Laniado et al., 1997). Since then, both α and β 
subunits have been detected in many cancer cell lines and in some patient biopsies. 
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VGSC α subunits are expressed in some cervical, ovarian, breast, and colon tumors in 
vivo (Fraser et al., 2005; House et al., 2010; Gao et al., 2010; Hernandez-Plata et al., 
2012), while, some prostate, breast, cervical, and lung cancers express β subunits 
[reviewed in (Patel and Brackenbury, 2015)]. Studies have identified both positive and 
negative associations between VGSC expression and metastatic potential. Nav1.5 
expression in breast cancer cells correlates positively with increased risk of recurrence 
and metastasis (Fraser et al., 2005; Yang et al., 2012), and a similar trend has been 
described for colon, prostate, and ovarian cancers. However, there is an inverse 
correlation between α expression and clinical grade in glioma and no correlation in lung 
cancer cell lines (Schrey et al., 2002; Onganer and Djamgoz, 2005; Roger et al., 2007). 
Expression of α subunits can potentiate lateral motility, adhesion, process extension, 
and other cellular behaviors associated with metastasis (Brackenbury, 2012). It is not 
clear how increased expression of the pore-forming α subunits potentiates invasive 
changes in the tumor cells. Three potential models have been proposed: increased Na+ 
influx enhances H+ efflux thus activating pH-dependent extracellular matrix degradation 
and invasion; regulation of an “invasion gene network,” particularly by SCN5A; and 
increased intracellular Ca2+ which enhances formation of invasive projections [reviewed 
in (Brackenbury, 2012)]. 
SCN1B and SCN2B expression are associated with metastatic potential in prostate 
cancer cells (Diss et al., 2008; Jansson et al., 2012). However, studies of the invasive 
potential of SCN1B-expressing breast cancer in vitro have been contradicted by in vivo 
studies. β1 expression is associated with less invasive breast cancer cell lines (Chioni 
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et al., 2009), however, in a mouse model of breast cancer, overexpression of β1 
increased tumor growth, metastasis, and angiogenesis (Nelson et al., 2014). β1 trans-
homophilic adhesion mediates process outgrowth from breast cancer cells (Nelson et 
al., 2014), thus it is proposed that β1 promotes metastasis by a mechanism similar to 
β1-mediated neurite outgrowth.  
New frontiers and novel techniques 
The list of pathogenic VGSC gene mutations is growing rapidly. The explosion of whole 
genome sequencing has led to multi-institution efforts such as the NINDS funded Epi4K 
Project (www.epi4k.org), with the goal of sequencing the genomes of 4000 patients with 
epilepsy, and the England Department of Health funded 100,000 Genomes Project 
(http://www.genomicsengland.co.uk/) (Kearney, 2014; Siva, 2015). However even with 
familial genetic information in hand, determining whether mutations are causative and 
understanding their pathophysiology are not simple tasks. A given patient can have 
mutations in several genes, which may be causative, benign, or modify another 
mutation. A single causative mutation may result in a wide range of phenotypes among 
individuals, for example, DS and GEFS+ patients may express the same SCN1A or 
SCN1B mutation. Genetic background is critical. Scn1a+/- mouse models of DS have 
phenotypes of varying severity depending on genetic background (Yu et al., 2006; Miller 
et al., 2014). This issue can now be addressed directly with the induced-pluripotent 
stem cell (iPSC) technique. Patient iPSCs, usually derived from a skin cell biopsy, can 
theoretically be differentiated into any cell type, including cardiomyocytes, and specific 
neuronal subtypes (Parent and Anderson, 2015). With this remarkable technique, we 
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now have the opportunity to study disease-causing mutations in human cells within the 
context of the patient’s unique genomic background (Takahashi et al., 2007). 
Furthermore, endogenous genes that may contribute to pathology remain present. Brain 
organoids made from human iPSC-derived cells with a mutation in a gene involved in 
pluripotent cell maintenance were used to model microcephaly, providing proof-of 
concept for use of organoids to model other neurological diseases (Lancaster et al., 
2013). Another advantage of iPSCs is the opportunity to perform drug screening on 
differentiated human cells, alongside animal models, thus providing insight into toxicity 
and species-specific effects prior to clinical trials [reviewed in (Ko and Gelb, 2014)]. 
Patient-derived iPSC cells are critical for precision medicine approaches. For instance, 
AED effectiveness or toxicity may be optimized on patient-derived iPSC-neurons prior to 
patient treatment. As the iPSC technique is further refined and developed, it will provide 
additional, critical tools in therapeutic development. 
Another challenge to the field is the non-specificity of clinically available VGSC-targeted 
drugs. There are 6 different potential sites for small molecule targeting on VGSCs, as 
demonstrated by the wide variety of toxin binding sites. However, most of the current 
anti-arrhythmic, anti-epileptic, and analgesic VGSC drugs on the market, e.g. 
lamotrigine, phenytoin, and lidocaine, target the ‘local anesthetic’ site located in domain 
IVS6 (Kwong and Carr, 2015). This site is highly conserved between α subunits, thus 
these drugs have little selectivity for specific VGSCs and often cause adverse effects. 
Development of VGSC agents that target other binding sites remains an important task. 
While, in most cases, toxins cannot be used directly for therapeutics, they can greatly 
inform drug design; small molecules can be developed that preserve beneficial effects 
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while reducing harm. Drugs targeting specific toxin binding sites may allow more 
selective blockade of specific α subunits to treat disease such as neuropathic pain, 
cardiac arrhythmias, epilepsies, and perhaps even cancer (Stevens et al., 2011; Xiao et 
al., 2014).  
Transgenic zebrafish are an economical and rapid vertebrate system that can be used 
to screen small molecule libraries and FDA-approved drugs for novel applications. 
Zebrafish with mutations in scn1Lab, the gene orthologous to SCN1A, have 
spontaneous seizures that are resistant to many AEDs and appear to model DS. Dr. 
Peter de Witte’s group showed DS zebrafish responded to fenfluramine (Zhang et al., 
2015). Dr. Scott Baraban used locomotion tracking in mutant zebrafish to monitor 
behavioral seizures in a drug screen, which was validated using diazepam, valproate, 
and stiripentol, AEDs effective in some DS patients. Out of 320 compounds tested, 
clemizole, an FDA-approved antihistamine, suppressed spontaneous seizures in vivo 
(Baraban et al., 2013). This approach can be adapted for screening potential 
therapeutics for any monogenic epilepsy, especially if combined with the CRISPR/Cas9 
technique. Discovered in 2010 as a bacterial defense mechanism against phages 
(Deveau et al., 2010), the CRISPR/Cas9 system has since been adapted to easily and 
quickly introduce heritable genetic mutations in mice, rats, zebrafish, and rabbits (Li et 
al., 2013; Chang et al., 2013; Yang et al., 2014a). Compared to zinc-finger nucleases 
and transcription activator-like effector nucleases (TALENs), CRISPR/Cas creates 
double-stranded DNA breaks in a sequence-specific manner at sites complementary to 
a ‘single-guide RNA.’ Because these are easy to design, the CRISPR/Cas9 system 
vastly improves the precision, speed, and accuracy of creating transgenic cell lines 
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(including iPSCs) and animal models for single gene mutations (Yang et al., 2014b). 
These and other cutting edge techniques will allow us to discover novel disease 
mechanisms and therapeutics for diseases linked to VGSC mutations for another six 
decades (Catterall, 2012). 
SCN1B-C121W: a GEFS+-associated VGSC mutation 
Prevalence of SCN1B-C121W 
The first VGSC gene mutation associated with epilepsy was a heterozygous SCN1B-
C121W mutation, associated with the mild epilepsy syndrome GEFS+ (Wallace et al., 
1998; Scheffer et al., 2007). This cysteine to tryptophan mutation at residue 122, 
encoded by c.363C>G (alternatively labeled as c.387C>G if the signal sequence is 
included) has been reported by six studies to date (Table 1.2)(Wallace et al., 1998, 
2002; Haider et al., 2005; Scheffer et al., 2007; Dibbens et al., 2010; Carvill et al., 
2014). A majority of these studies report the presence of the mutation in Australian 
families with hereditary epilepsy. One study looking at 123 unrelated patients with 
idiopathic generalized epilepsies in Kuwait found three of these individuals carried 
c.363C>G in SCN1B. These patients also experienced febrile seizures (Haider et al., 
2005)1. In total, 54 individuals with SCN1B-C121W have been reported, 9 of which were 
unaffected carriers. The remaining patients have a spectrum of heterogeneous epilepsy 
phenotypes (Table 1.2). Many of these patients have febrile seizures and other milder 
                                            
1 This study concluded that this mutation was not the cause of the patients’ epilepsy symptoms on the 
rationale that there were only 2% of their patient population that carried this mutation. However, this 
frequency is in agreement with (or a little higher) than the incidence of GEFS+ patients with SCN1B-
C121W mutations. A study of these patients’ families to see if there was a history of epilepsy within the 
other family members who also carried the SCN1B-C121W mutation would further elucidate whether 
SCN1B-C121W contributed to the idiopathic generalized epilepsies and febrile seizures seen in these 
Kawaitian patients. 
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seizure phenotypes. Surprisingly, one proband with DS has been reported to be 
heterozygous for SCN1B-C121W, with no mutations in other known epilepsy genes 
(Carvill et al., 2014). Although the proband’s mother and grandmother are also 
heterozygous for SCN1B-C121W, the mother has febrile seizures and the grandmother 
has no epilepsy phenotype (Carvill et al., 2014). This recent report further supports the 
hypothesis that while SCN1B-C121W contributes to epilepsy in these patients, genomic 
and epigenomic background and environmental factors may also play important roles in 
determining the phenotypic severity of an individual. 
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Table 1.2 Reports of Patients with SCN1B-C121W 
Reference Starting screen # Families 
# individuals 
with 
mutation 
Diagnoses 
Location of 
patients 
(Wallace et al., 1998) 
  1 18 
Unclassified seizures (1), 
FS+ (6), FS (6), myoclonic 
ataxic epilepsy (1), FS and 
absences (1), Unaffected 
(3) 
Australia 
(Wallace et al., 2002) 
  1 16 
FS (6), FS+ (6), FS & 
partial epilepsy (1), GTCS 
(1), unaffected (4) 
Australia 
(Haider et al., 2005) 123 unrelated patients with 
idiopathic generalized epilepsy 
  3 IGE with FS (3) Kuwait 
(Scheffer et al., 2007) 
402 probands with seizure 
disorders 
2* 13 
FS (7), FS+ (1), TLE (1), 
TLE & FS+ (1), TLE & FS 
(2), unaffected (1) 
Australia 
(Dibbens et al., 2010)  
 Patients with GEFS+, looking 
for HCN2 mutations 
N/a 1 
FS, included in (Wallace et 
al., 1998) 
Australia 
(Carvill et al., 2014) 13 DS patients, negative for 
SCN1A mutations (parents were 
also sequenced when possible) 
1 3 
DS (1), FS(1), unaffected 
(1) 
Not reported 
*these two families and the families from (Wallace et al., 1998, 2002) share a haplotype – suggesting a founder mutation 
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Although the term “GEFS+” was used previously to describe a spectrum of seizure 
disorders, this terminology has rapidly changed. Advances in genetic testing and 
seizure classifications are creating subdivisions within clinical diagnoses once 
considered indistinguishable. As exome sequencing initiatives like Epi4K (Epi4K 
Consortium, 2012) have implicated more genes associated with epilepsy syndromes, 
the field is debating whether epilepsies with similar phenotypes but different genetic 
origins have converging pathophysiological mechanisms or not. The answer to this 
question could impact which therapies are effective for patients. Therefore, although I 
refer to SCN1B-C121W as a GEFS+-associated mutation, in clinical practice, this refers 
to a very heterogeneous patient population.   
Heterologous studies of SCN1B-C121W 
A majority of the literature studying SCN1B-C121W has focused on heterologous over 
expression and, similar to other studies of VGSC physiology, these findings are mostly 
dependent on cell type and VGSC α subunit expressed. I have summarized studies that 
compare effects of β1 and β1-C121W in Table 1.3. I will discuss how some of the 
differences observed between β1 and β1-C121W modulation of VGSC α subunits may 
contribute to altered Na+ current. In addition, the pathophysiological mechanisms 
proposed from these in vitro studies may not be applicable to neurons in vivo. A major 
difference is that most in vitro studies have a single VGSC α subunit expressed, while in 
vivo changes in a single VGSC α subunit may result in compensatory changes in other 
channels.
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Table 1.3 Heterologous results of β1 or β1-C121W expression 
 
 
Effect from β1-WT 
expression 
Effect from β1-C121W 
expression 
VGSC α subunit Cell line Reference 
Biotinylation of surface 
proteins 
Both present at the surface N/A 1610 (Patino et al., 2011) 
β1 trans-homophilic 
adhesion 
aggregation of cells no aggregation of cells N/A 
Drosophila 
S2 cells 
(Meadows et al., 
2002) 
Saxitoxin binding of 
VGSC α 
both ↑ surface α expression Nav1.2  1610 
(Meadows et al., 
2002) 
Coimmunoprecipitation 
with VGSC α 
both associate Nav1.3 CHO 
both associate Nav1.2  1610 
both associate Nav1.1 HEK (Aman et al., 2009) 
Sodium current density 
both ↑ current density similarly Nav1.4 HEK 
(Tammaro et al., 
2002) 
↑ current density less ↑ current density hNav1.1-M1841T* tsA-201 
(Rusconi et al., 
2007) 
VGSC α mRNA 
expression 
↑ Nav1.3, ↑ Nav1.6 ↑ Nav1.3, ↓ Nav1.6 
endogenously express 
Nav1.1, Nav1.2, 
Nav1.3, Nav1.6 
GH3 
(Baroni et al., 2013) 
↑ Nav1.2, ↑ Nav1.4, 
 ↑ Nav1.6, ↓ Nav1.5 
↑ Nav1.2, ↑ Nav1.6 
endogenously express 
Nav1.5 
H9C2 
VGSC α protein 
expression 
↑ total VGSC α 
expression 
no increase in total VGSC 
α expression 
endogenously express 
Nav1.1, Nav1.2, 
Nav1.3, Nav1.6 
GH3 
↑ Nav1.2, ↑ Nav1.6 ↑ Nav1.3, ↓ Nav1.6 
↑ total VGSC α expression 
endogenously express 
Nav1.5 
H9C2 ↑ Nav1.2, ↑ Nav1.4, 
 ↑ Nav1.6, ↓ Nav1.5 
↑ Nav1.2, ↑ Nav1.6 
Slow inactivation 
constant 
↓ 
 
no effect 
 
Nav1.2  
Xenopus 
oocytes 
(Wallace et al., 
1998) 
↓ no effect 
Nav1.4 or Nav1.2 
Xenopus 
oocytes 
(Moran and Conti, 
2001) 
β1-WT + β1-C121W coexpression – intermediate effect 
on slow inactivation 
Recovery from 
inactivation 
lengthens recovery no effect 
Nav1.3 CHO (Meadows et al., 
2002) Nav1.2  1610 
hastens recovery no effect Nav1.4  HEK 
(Tammaro et al., 
2002) 
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Effect from β1-WT 
expression 
Effect from β1-C121W 
expression 
VGSC α subunit Cell line Reference 
Voltage-dependence of 
inactivation 
no effect 
shifted to more negative 
voltages 
endogenously express 
Nav1.1, Nav1.2, 
Nav1.3, Nav1.6 
GH3 
(Baroni et al., 2013) 
shifted toward more positive voltages 
endogenously express 
Nav1.5 
H9C2 
no effect Nav1.3 CHO (Meadows et al., 
2002) no effect Nav1.2  1610 
Voltage-dependence of 
activation 
no effect Nav1.2   1610 (Meadows et al., 
2002) no effect Nav1.3 CHO 
no effect no effect 
endogenously express 
Nav1.1, Nav1.2, 
Nav1.3, Nav1.6 
GH3 
(Baroni et al., 2013) 
shifted toward more positive voltages 
endogenously express 
Nav1.5 
H9C2 
Fraction of channels 
available at subthreshold 
membrane potentials† 
~10mV shift in 
availability curve to more 
negative voltages. 
No shift 
Nav1.3 CHO 
(Meadows et al., 
2002); (Lucas et al., 
2005) β1-WT + β1-C121W coexpression – same shift as β1-
WT alone 
Frequency-dependent 
rundown 
~60% decline only 20-30% decline Nav1.2  1610 
(Meadows et al., 
2002) 
~60% decline only 20-30% decline 
Nav1.3 CHO β1-WT + β1-C121W coexpression – same decline as 
β1-WT alone 
At elevated temperatures 
(34˚C) 
Compared to WT, β1-C121W caused ↓use-dependent 
inactivation, ↑ persistent current, ↑ window current, 
delayed onset of inactivation, and accelerated recovery 
from inactivation 
Nav1.2   CHO (Egri et al., 2012) 
Drug sensitivity 
sensitive to phenytoin less sensitive to phenytoin Nav1.3  CHO (Lucas et al., 2005) 
sensitive to lacosamide 
at RT and 34˚C 
not sensitive to lacosamide 
at RT and 34˚C 
Nav1.2  CHO 
(Abdelsayed et al., 
2013) 
Coimmunoprecipitation 
with β4 
associates with β4 n/a HEK (Aman et al., 2009) 
Modulation of β4 effect 
on resurgent sodium 
current ‡ 
reduction in persistent 
current 
no reduction in persistent 
current 
Nav1.1 + β4 HEK (Aman et al., 2009) 
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Effect from β1-WT 
expression 
Effect from β1-C121W 
expression 
VGSC α subunit Cell line Reference 
* hNav1.1-M1841T is a trafficking-deficient GEFS+ mutant 
† To test this, cells are held at a long conditioning pulse of various potentials, followed by a test pulse. 
‡ Resurgent current occurs as Na+ channels are blocked by a blocking particle, postulated to be β4, at positive voltages, during depolarization, 
and then become unblocked during repolarization. To measure this, we step to a positive voltage, to stimulate an AP, and then then step back 
down to different voltages. Then we can measure the extent of resurgent current seen when you step back down. This is generally higher with 
presence of β4 or a β4 peptide, although it does depend on the cell type and VGSC α subunit expressed. 
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It is important to remember, as discussed earlier in this chapter, that epilepsy mutations 
may not affect inhibitory and excitatory neurons in the same manner in vivo. VGSC α 
subunit expression varies between different subpopulations and these cell types may be 
differentially affected by an epilepsy mutation. Epilepsy results from an imbalance 
between excitation and inhibition, so overall increased excitation, decreased inhibition, 
or a combination of both can contribute to network hyperexcitability. This does not mean 
that in an epileptic brain all excitatory neuronal populations will be hyperexcitable and all 
inhibitory neuronal populations will be hypoexcitable. Recall that recent studies of DS 
patient derived induced pluripotent stem cell (iPSC) neurons showed that both inhibitory 
and excitatory neurons are hyperexcitable compared to non-epileptic controls (Liu et al., 
2013). 
β1 and β1-C121W modulation of sodium channels and INa 
An important function of β1 is to promote sodium channel cell surface expression. β1-
C121W is expressed at the cell surface in heterologous cells, including Xenopus 
oocytes, Drosophila S2 cells, and transfected fibroblasts, and co-immunoprecipitates 
with some VGSC  subunits, including Nav1.1, Nav1.3, and Nav1.4 (Meadows et al., 
2002; Aman et al., 2009; Patino et al., 2011). β1-C121W is capable of promoting 
sodium channel cell surface expression and increasing sodium current density, similar 
to β1-WT, in some systems (Tammaro et al., 2002; Meadows et al., 2002). However, 
while β1-WT was reported to increase cell surface expression of a trafficking-defective 
SCN1A GEFS+ mutant protein, hNav1.1-M1841T, β1-C121W only had a partial effect 
on promoting the cell surface expression of this mutant (Rusconi et al., 2007). Therefore 
SCN1B-C121W has the potential to aggravate other epilepsy-associated mutations. 
35 
 
β1 expression can also modulate mRNA and protein expression of VGSC α subunits. 
This is postulated to occur through sequential cleavage of 1 by BACE and -secretase, 
leading to nuclear translocation of the 1 intracellular domain and its subsequent 
modulation of gene expression (Kim et al., 2005, 2007, 2011; Wong et al., 2005). For 
example, in both a rat pituitary cell line (GH3) and a rat cardiac myocyte cell line 
(H9C2), total VGSC protein expression and INa density was increased with WT-β1 cDNA  
transfection. In contrast, β1-C121W expression increased VGSC protein expression in 
H9C2 but not in GH3 cells (Baroni et al., 2013). When specific VGSC α subunit 
expression was examined, β1 and β1-C121W had differing effects. β1-WT increased, 
but β1-C121W decreased, Nav1.6 mRNA and protein expression, in GH3 cells (Baroni 
et al., 2013). β1-WT overexpression in H9C2 cells induced expression of Nav1.2, 
Nav1.4, and Nav1.6 mRNA and protein but decreased Nav1.5 mRNA and protein. In 
contrast, β1-C121W expression induced Nav1.2 and Nav1.6 expression, but did not 
affect Nav1.5 in the same cell line (Baroni et al., 2013). These results emphasize how 
β1 and β1-C121W modulation of VGSCs are cell-type and VGSC α subunit specific. 
In general, β1-WT, but not β1-C121W, reduced the slow inactivation component of 
sodium current (Wallace et al., 1998; Moran and Conti, 2001). SCN1B-C121W 
abolishes the modulatory effects of β1 on sodium current recovery from fast inactivation 
(Tammaro et al., 2002; Meadows et al., 2002). We previously observed lengthening of 
recovery from inactivation with β1 expression. Therefore, since β1-C121W does not 
have this effect in some cell types, channels are available sooner after an action 
potential, which could lead to a more excitable phenotype (Meadows et al., 2002). 
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Voltage-dependence of activation and inactivation are not different with β1-C121W 
expression compared to β1 expression (Meadows et al., 2002; Baroni et al., 2013). 
However, the voltage-dependence of inactivation is shifted to more negative voltages 
when β1-C121W was expressed in GH3 cells compared to β1-WT (Baroni et al., 2013). 
Depending on the neuronal cell type, these changes in channel inactivation ranges and 
voltage dependence of inactivation could lead to changes in excitability. For example, in 
pyramidal neurons, a negative shift in sodium channel voltage-dependence of 
inactivation could lead to hyperexcitability because more channels will be available for 
activation at a given potential compared to cells expressing β1-WT. However, as this 
cell type originates from rat heart, this may not have relevance for the GEFS+ 
phenotype of SCN1B-C121W patients. 
There are several other notable differences seen between β1-WT and β1-C121W, 
which could contribute to overall network hyperexcitability and a seizure phenotype. β1-
WT, but not β1-C121W, negatively shifts the availability of channels at subthreshold 
membrane potentials. Therefore, more Nav1.3 channels were available at subthreshold 
voltages when co-expressed with β1-C121W, which could increase sodium current 
amplitude (Meadows et al., 2002; Lucas et al., 2005). Furthermore, β1-C121W failed to 
increase frequency-dependent rundown over time compared to β1-WT (Meadows et al., 
2002). 
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Modulation of β4 effect on resurgent sodium current 
As discussed previously, β4 is critical for resurgent Na+ current,2 and β1 is capable of 
modulating the effects of β4 on resurgent current. We have previously hypothesized that 
β4 acts like the “gas” – promoting resurgent current, while β1 acts as a “brake” – 
reducing resurgent current. Like β1, β1-C121W associates with β4 (Aman et al., 2009), 
but β1-C121W is unable to reduce persistent current, unlike β1-WT. Therefore 
increased persistent current, and thus a prolongation of Na+ current, could contribute to 
altered neuronal firing patterns (Aman et al., 2009).  
Does β1-C121W have dominant-negative effects? 
Since GEFS+ patients are heterozygous for SCN1B-C121W, it is possible that β1-
C121W acts in a dominant-negative function by associating with VGSC α subunits and 
preventing them from trafficking and/or being modulated by β1-WT. When both β1-WT 
and β1-C121W were co-expressed with Nav1.4 in oocytes, an intermediate rate of 
inactivation was measured compared to either  subunit alone, suggesting that β1-
C121W antagonizes β1-WT in this system (Moran and Conti, 2001). However, CHO 
cells expressing Nav1.3 + β1-WT + β1-C121W and Nav1.3 + β1-WT had a similar 
negative shift in the V1/2 of channel availability and an increase in frequency-dependent 
                                            
2 Resurgent current occurs as Na+ channels are blocked by a blocking particle, 
postulated to be β4, at positive voltages, during depolarization, and then become 
unblocked during repolarization. To measure this, we step to a positive voltage, to 
stimulate an AP, and then then step back down to different voltages. Then we can 
measure the extent of resurgent current seen when you step back down. This is 
generally higher with presence of β4 or a β4 peptide, although it does depend on the 
cell type and VGSC α subunit expressed. 
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rundown. In the same study, β1-C121W was unable to modulate these properties of 
Nav1.3 (Meadows et al., 2002). Therefore, β1-C121W appears to have dominant-
negative effects in some models, but not others. Altogether, these data from 
heterologous systems emphasizes the importance of in vivo studies for clarifying the 
pathophysiological impact of SCN1B-C121W. 
Disruption of trans-homophilic cell adhesion by SCN1B-C121W 
The immunoglobulin domain of β1 shares homology with other cell adhesion molecules 
including myelin P0. The 1 Ig loop contains a single, intramolecular, disulfide bond 
between Cys121 and Cys45. Therefore, upon the discovery of SCN1B-C121W this 
mutation was hypothesized to abolish this disulfide bond and disrupt homophilic 
adhesion. In 2012, Barbieri and colleagues used 2D-diagonal SDS-PAGE analysis to 
confirm the disruption of a disulfide bond in the Ig loop by the SCN1B-C121W mutation 
(Barbieri et al., 2012). We have shown evidence of disrupted β1-mediated homophilic 
adhesion by the SCN1B-C121W mutation in Drosophila S2 cells (Malhotra et al., 2000; 
Meadows et al., 2002). S2 cells have no endogenous cell adhesion molecules so 
heterologous expression of homophilic cell adhesion molecules results in cellular 
aggregation. When expressed in S2 cells, β1-WT, but not β1-C121W, induces high 
affinity cellular aggregation (Malhotra et al., 2000; Meadows et al., 2002). These results 
suggest β1-C121W is incapable of trans-homophilic adhesion. β1- and β1B-mediated 
trans-homophilic adhesion promote neurite outgrowth in cultured neurons (Patino et al., 
2011). Therefore, p.C121W may result in neuronal pathfinding and fasciculation defects 
similar to what we have reported in Scn1b-null mice (Brackenbury et al., 2008). 
Decreased dendritic arborization in subicular neurons of mice homozygous for Scn1b-
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C121W (Reid et al., 2014) may be due to the loss of β1-mediated trans-homophilic 
adhesion. Although β1-C121W cannot interact homophilically with other β1-C121W 
molecules (Malhotra et al., 2000; Meadows et al., 2002), to date no studies have 
determined whether β1-C121W is capable of interacting with β1-WT. As GEFS+ 
patients are heterozygous for SCN1B-C121W, this is an important question for 
understanding how SCN1B-C121W affects neuronal development. 
Effects on potassium channels 
Several investigators have found evidence that β1 modulates potassium channels, 
summarized in Table 1.4. Marrioneau et al. (2012) immunoprecipitated Kv4.2 and found 
a β1 extracellular peptide associated via mass spectroscopy and proteomic analysis 
(Marionneau et al., 2012). β1 co-localizes with Kv1.2 at axon initial segments in the 
mouse brain (Nguyen et al., 2012). Heterologously co-expressed FLAG-tagged β1 and 
Kv1.2 associate as assessed by co-immunoprecipitation. β1 modulates K+ current 
when co-expressed with Kv1 or Kv7 channels in Xenopus oocytes (Nguyen et al., 
2012). However, β1 does not appear to modulate Kv3 channels. Using P0-β1 chimeras, 
the authors showed that the external Ig domain was critical for β1-mediated acceleration 
of Kv1.3 activation. β1-C121W was unable to modulate Kv1.3 activation (Nguyen et al., 
2012). In contrast, β1 and β1-C121W both slowed Kv1.1 deactivation (Nguyen et al., 
2012). Together, this evidence suggests that studies of SCN1B mutations need to 
consider that potassium currents, not just sodium currents, may be altered.
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Table 1.4 Heterologous effects of β1 on K+ channels 
 Effect from β1-WT expression 
Effect from β1-
C121W expression 
Cells/tissue Reference 
Coimmunoprecipitation 
associates with Kv4.2, as identified by 
mass spectrometry 
not tested mouse brain  
(Marionneau et al., 2012) 
β1-EYFP associates with Kv4.2 not tested HEK 
β1-V5 associates with Kv1.2-flag, 
Kv7.2-flag 
not tested HEK (Nguyen et al., 2012) 
Modulation of K+ current 
modulates Kv1 and Kv7, but not Kv3 
channels 
 
accelerated Kv1.3 activation 
 
slows Kv1.1 deactivation 
 
 
 
did not accelerate 
Kv1.3 activation 
 
slows Kv1.1 
deactivation 
HEK (Nguyen et al., 2012) 
41 
 
Effect on drug sensitivity and excitability at higher temperatures 
Of therapeutic interest is whether SCN1B-C121W alters the pharmacological sensitivity 
of sodium channels in patients. In vitro, Nav1.3 channels were less sensitive to 
phenytoin and Nav1.2 channels were less sensitive to lacosamide when co-expressed 
with β1-C121W, compared to β1-WT (Lucas et al., 2005; Abdelsayed et al., 2013). 
Due to the febrile seizure phenotype in many GEFS+ patients (Wimmer et al., 2010), 
one study has examined whether β1-C121W has altered current modulatory effects 
compared to β1-WT at 34˚C, a temperature which is closer to physiological 
temperatures than the 22-25˚C most in vitro studies use. At this elevated temperature, 
CHO cells expressing Nav1.2 and β1-C121W had decreased use-dependent 
inactivation, increased persistent current and window current, and delayed onset of, and 
accelerated recovery from, fast inactivation compared to cells expressing Nav1.2 and 
β1-WT (Egri et al., 2012). This study did not repeat these studies at 22-25˚C to 
determine if the differences with β1-C121W expression was specific to their model or 
the elevated temperatures they used. Thus, β1-C121W appears to lack a protective 
effect against increased excitability at elevated temperatures. However, although CHO 
cells are mammalian in origin, they have distinctly different protein expression and 
physiology from neurons so this result may not apply to neurons in vivo. 
In vivo effects of SCN1B-C121W 
A knock-in Scn1b-C121W mouse model of GEFS+ was reported in 2010 (Wimmer et 
al., 2010). Heterozygotes (Scn1b+/W), which model GEFS+, and homozygotes 
(Scn1bW/W) from this model are more sensitive to thermally-induced seizures (Wimmer 
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et al., 2010). In addition Scn1bW/W mice experience spontaneous seizures, beginning 
around post-natal day 14, and early lethality by post-natal day 21, similar to Scn1b null 
mice and are thus thought to model the severe epileptic encephalopathy, Dravet 
Syndrome (Chen et al., 2004; Wimmer et al., 2010). Researchers have been interested 
in confirmation or rejection of previous heterologous results regarding β1-C121W 
function. As most of these in vitro results were done with only β1-WT or β1-C121W 
present, most studies of this mouse model have focused on comparing Scn1bW/W and 
Scn1b+/+. In Table 1.5, I summarized the in vivo findings regarding Scn1b-C121W. I will 
focus on describing those studies that are most relevant to the experiments that I have 
performed. 
Establishing how p.C121W results in changes in neuronal excitability is critical to 
understanding the mechanisms underlying epileptogenesis and/or seizure phenotype. 
For example, an epilepsy-causing mutation may alter the balance between excitatory 
and inhibitory signals by causing hyperexcitability of excitatory neurons and/or 
hypoexcitability of inhibitory neurons. Some studies suggest that epilepsies can be 
caused by “interneuronopathies” or dysfunction of the inhibitory neurons, as these 
models show decreased excitability in inhibitory neurons, thus disrupting the 
excitatory/inhibitory balance (Yu et al., 2006; Ogiwara et al., 2007; Oakley et al., 2011). 
Interestingly, evidence suggests that smaller sub-populations of neurons, such as the 
parvalbumin-positive interneurons, or layer II/III cortical pyramidal neurons for example, 
can each be modulated differentially by ion channel mutations and play critical roles in 
epilepsy. Therefore, determining not only how p.C121W alters neuronal excitability, but 
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which neuronal populations are affected is key to understanding the mechanisms 
underlying SCN1B-C121W-linked epilepsy. 
β1 sub-cellular localization in vivo 
Another important consideration is whether β1-C121W can localize to the appropriate 
subcellular domains of neurons in vivo. The two neuronal subcellular domains most 
often considered for VGSC α and β subunit localization are the axon initial segment and 
the nodes of Ranvier. Virally expressed β1-C121W-EGFP in a wildtype mouse 
appeared to localize to the AIS in many brain regions. However the data did not suggest 
AIS surface localization (Wimmer et al., 2010). In contrast, the same group later 
reported that Scn1bW/W mice have no β1-positive AIS domains in the subiculum 
(Wimmer et al., 2015). Although changes in β1 expression in vitro resulted in altered 
sodium channel expression (Baroni et al., 2013), as discussed above, Wimmer et al. 
reported no difference in Nav1.1, Nav1.2 , and Nav1.6 distribution along the AIS in the 
hippocampus of Scn1bW/W mice (Wimmer et al., 2010). Here, we sought to build on 
these previous studies to compare β1 localization in Scn1b+/W, Scn1b+/-, and Scn1bW/W 
brains, using Scn1b-/- brains as negative controls. β1 localization in Scn1b+/W mice has 
not been reported previously. This experiment is critical to understand the mechanism 
of GEFS+, in which patients express one WT and one mutant SCN1B allele. In addition, 
we compared 1 and β1-C121W localization in the cortex, which is relevant to epilepsy, 
and in the cerebellum, which may be relevant to co-morbid effects of epilepsy 
syndromes. 
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Table 1.5 In vivo results from Scn1b-C121W mice 
 Scn1b+/+ mice Scn1b+/W mice Scn1bW/W mice Tissue Reference 
Immunohistochemistry of 
β1 
virally expressed β1-
C121W-EGFP 
appears to traffic to 
AIS 
  
pyramidal CA3 neurons in 
hippocampus; pyramidal 
neurons in the subiculum; 
layer 2/3 pyramidal neurons 
in primary somatosensory 
cortex; Purkinje cell in the 
cerebellum 
(Wimmer et al., 
2010) 
~95% AIS are β1+ ~50% AIS are β1+ 0% AIS are β1+ mouse subiculum 
(Wimmer et al., 
2015) 
Nav1.1, Nav1.2, and 
Nav1.6 distribution along 
the AIS 
no differences between Scn1b+/+ and Scn1bW/W  
molecular layer of the 
hippocampus 
(Wimmer et al., 
2010) 
Dendritic arborization ↓ in Scn1bW/W neurons compared to Scn1b+/+ subicular neurons (Reid et al., 2014) 
Intrinsic bursts in response 
to current injectionsφ 
No difference in total number of burst 
events or frequency of APs within bursts; 
Scn1b+/W mice had longer burst duration 
compared to Scn1b+/+ mice 
 
subicular pyramidal neurons 
of P14-16 mice at 34˚C 
(Wimmer et al., 
2010); 
(Reid et al., 2014) 
Tonic firing following 
intrinsic burstsφ 
↑ frequency in Scn1b+/W mice and Scn1bW/W 
AP threshold 
-48.74 ± 0.32 mV -51.43 ± 0.23 mV  
(Wimmer et al., 
2010) 
-50.91 ± 2.66 mV  -47.01 ± 2.91 mV 
(Reid et al., 2014) 
Resting membrane 
potential 
-71.69 ± 1.47 mV  -66.64 ± 1.72 mV 
AP frequency (input-output 
curve) 
↑ (left-shift in the curve) in Scn1bW/W compared to Scn1b+/+ 
cortical layer 2/3 pyramidal 
neurons 
Proportion of burst firing 
neurons 
56%  81% 
subicular pyramidal neurons 
of P14-16 mice at 34˚C 
Spontaneous PSCs ↓ sPSC inter event interval in Scn1bW/W compared to Scn1b+/+ subiculum, but not CA1 
AP characteristics 
No change in amplitude, half-width, rise, threshold, or resting 
membrane potential between Scn1b+/+ and Scn1bW/W 
Cortical layer 2/3 pyramidal 
neurons; 
CA1 interneurons (@ 22˚C 
and 34˚C); Cortical layer 5 
pyramidal neurons; CA1 
pyramidal neurons 
(Reid et al., 2014) 
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 Scn1b+/+ mice Scn1b+/W mice Scn1bW/W mice Tissue Reference 
CA1 oscillations 
In Scn1b+/W compared to Scn1b+/+: 
↑ number of spikes/oscilation;  
↑ event duration; 
↓ latency to oscilation onset; 
↓ interspike interval 
 
CA1 hippocampal neurons 
from P16-P21 at 32˚C 
(Hatch et al., 
2014) 
no change in spikes/oscilation; 
no change in event duration 
 
CA1 hippocampal neurons 
from P16-P21 at 28˚C 
Difference in CA1 
oscillations with 
carbamazepine  
 
OR 
 
retigabine 
↓ number of 
spikes/oscilation 
(10μM CBZ) 
no change in event 
duration (10μM CBZ) 
 
↓ number of 
spikes/oscilation (1μM 
RTG) 
↓ event duration (1μM 
RTG) 
↓ number of 
spikes/oscilation 
(1μM CBZ) 
↓ event duration 
(10μM CBZ) 
 
↓ number of 
spikes/oscilation 
(0.3 μM RTG) 
↓ event duration 
(1μM RTG) 
 
CA1 hippocampal neurons 
from P16-P21 at 32˚C 
Thermal seizure sensitivity 
Mean seizure onset 
~38.5˚C 
↓ 0.44 ± 0.17˚C ↓ 1.2 ± 0.15˚C P14-16 mice 
(Wimmer et al., 
2010) 
Effect of diazepam on 
latency to thermal seizure 
 
↑ time to seizure, 
dose-dependent 
P14-17 mice 
(Reid et al., 2014) Effect of stiripentol or 
lamotrigene on latency to 
thermal seizure 
 
stiripentol: ↑ time 
to seizure 
lamotrigine: no 
effect 
P14-17 mice 
Effect of retigabine on 
latency to thermal seizure 
↑ time to seizure ↑ time to seizure 
↑ time to seizure,  
dose-dependent 
P14-17 mice 
(Reid et al., 2014); 
(Hatch et al., 
2014) 
AIS – axon initial segment; AP – action potential; PSC – postsynaptic current; SPSC – spontaneous postsynaptic current; RTG – retigabine; CBZ - 
carbamazepine 
φ This is an intrinsic property of most subicular pyramidal neurons. 
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In vivo functional studies of network and neuronal excitability 
Studies comparing Scn1b+/W and wildtype littermates have only examined subicular 
pyramidal neurons and CA1 hippocampal neurons (Wimmer et al., 2010; Hatch et al., 
2014). A subset of subicular pyramidal neurons respond to current injections with 
intrinsic burst events followed by tonic firing. Scn1b+/W mice had an increased number of 
burst events, and longer burst duration, as well as an increase frequency of tonic firing 
compared to Scn1b+/+ mice (Wimmer et al., 2010). A separate study examined CA1 
network oscillations in Scn1b+/W and wild-type brain slices. CA1 oscillations were 
induced by stimulating the stratus oriens and recording extracellular potentials (Hatch et 
al., 2014). These oscillations could be reduced by pharmacological blockade of AMPA 
receptors or GABAA receptors, indicating both excitatory and inhibitory neurons were 
present in this circuit. In addition, severing connections between CA1 and CA3 did not 
affect oscillations (Hatch et al., 2014). When CA1 oscillations were measured at 32˚C, 
Scn1b+/W slices had more spikes per oscillation, greater event duration, decreased 
interspike interval and decreased latency to oscillation onset compared to wild-type 
controls. However, no differences were seen between Scn1b+/W and wild-type slices 
when measured at 28˚C (Hatch et al., 2014). Both Scn1b+/W and wild-type CA1 
oscillations decreased in number of spikes per oscillation in response to carbamazepine 
or retigabine, although Scn1b+/W responded at lower doses than wild-type (Hatch et al., 
2014). A few patients with SCN1B-C121W-associated GEFS+ have hippocampal 
sclerosis and temporal lobe epilepsy, but this does not describe all SCN1B-C121W 
GEFS+ patients (Table 1.2, (Scheffer et al., 2007)). Therefore, it is unclear whether 
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these observations in the CA1 contribute to the GEFS+ phenotype for a majority of 
patients with a SCN1B-C121W mutation. 
Other studies comparing Scn1bW/W mice, which model DS, with wild-type littermates are 
summarized in Table 1.5. Briefly Scn1bW/W subicular pyramidal neurons in brain slices 
at 34˚C showed a more positive threshold for action potential firing and a more positive 
resting membrane potential (Reid et al., 2014). Subicular pyramidal neurons in 
Scn1bW/W mice also had decreased spontaneous postsynaptic current inter-event 
intervals compared to wild-type mice. Both subicular and cortical layer II/III pyramidal 
neurons showed increased action potential firing frequency in response to current 
injection, resulting in a leftward shift in the input-output relationship (Reid et al., 2014). 
No changes in action potential amplitude or threshold were observed in several other 
brain regions including cortical layer II/III or layer V pyramidal neurons and CA1 
interneurons or pyramidal neurons (Reid et al., 2014). 
Conclusion 
VGSCs are integral to normal neuronal physiology and are important therapeutic targets 
for treating epilepsy. Understanding how mutations in VGSC genes lead to 
hyperexcitability in the brain is critical for understanding epilepsy pathophysiology and 
the identification of novel therapeutic targets. Heterozygous SCN1B-C121W mutations 
are associated with GEFS+. While heterologous over expression studies of this 
mutation have shown many cell type specific and VGSC α-subunit specific effects, it is 
unclear how these results translate in vivo.  The recent generation of a SCN1B-C121W 
knock-in mouse model has made it possible to study the in vivo effects of this mutation. 
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However, studies to date have not yet elucidated whether SCN1B-C121W is a loss-of-
function or a potential deleterious gain-of-function mutation. In this thesis, I directly 
compare Scn1b+/W and Scn1b+/- mice to address this important question. 
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Chapter 2. β1-C121W is down but not out: Epilepsy-
associated Scn1b-C121W results in a deleterious 
gain-of-function 
This chapter is in preparation for submission to The Journal of Neuroscience. We plan 
to submit it prior to my thesis defense on Nov 20th. 
Larisa Kruger conducted the majority of data collection and all data analysis for Figure 
2.1. Larisa Kruger also completed all data collection and analysis for Figures 2.2-2.5. 
Heather O’Malley collected and quantified data for Figure 2.6. Jacob Hull performed 
primary neuronal cultures for Figure 2.3. Amanda Kleeman performed some of the 
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Introduction 
Voltage-gated sodium channels (VGSCs), composed of one pore-forming  and two  
subunits in brain (Hartshorne and Catterall, 1981), are critical for neuronal excitability, 
including action potential initiation and conduction. While VGSC  subunits do not form 
the ion-conducting pore, they are essential for normal excitability in vivo through 
modulation of sodium and potassium currents (Isom et al., 1992, 1995b; Chen et al., 
2004; Marionneau et al., 2012). In addition,  subunits are immunoglobulin (Ig) 
superfamily cell adhesion molecules that play important roles in neuronal proliferation 
and migration, neurite outgrowth, neuronal pathfinding, and axonal fasciculation in vitro 
and in vivo (Davis et al., 2004; Brackenbury and Isom, 2008, 2011; Patino and Isom, 
2010; Patino et al., 2011). 
Mutations in VGSC genes are associated with multiple genetic epilepsies, including 
Genetic Epilepsy with Febrile Seizures plus (GEFS+) (Scheffer and Berkovic, 1997; 
Singh et al., 1999) and Dravet syndrome (Patino et al., 2009). Autosomal dominant 
mutations in SCN1B, encoding VGSC β1 and 1B, are associated with GEFS+ 
(Wallace et al., 1998, 2002; Scheffer et al., 2007).  SCN1B-C121W, the first reported 
GEFS+ mutation, disrupts a critical, intramolecular disulfide bond within the extracellular 
β1 Ig loop domain (Wallace et al., 1998; Audenaert et al., 2003; Barbieri et al., 2012). 
The impact of the SCN1B-C121W GEFS+ mutation on β1 subunit function is 
incompletely understood. Wildtype (WT) 1 subunits promote cellular aggregation in 
vitro via trans-homophilic cell-cell adhesion (Malhotra et al., 2000). In contrast, while 
mutant 1-C121W subunits are expressed at the cell surface in heterologous cells, they 
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do not participate in trans homophilic adhesion when tested in a cellular aggregation 
assay (Meadows et al., 2002).  The effects of mutant 1-C121W subunit expression on 
VGSC function have been extensively investigated in heterologous systems, but results 
are cell-type and VGSC α-subunit specific (Moran and Conti, 2001; Tammaro et al., 
2002; Meadows et al., 2002; Lucas et al., 2005; Aman et al., 2009; Egri et al., 2012; 
Baroni et al., 2013). In vivo studies of the heterozygous Scn1b+/W GEFS+ knock-in 
mouse model showed changes in action potential threshold and brain region-specific 
changes in AP firing at elevated temperatures (Wimmer et al., 2010; Reid et al., 2014) .  
In addition, Scn1b+/W mice showed differences in dendritic branching in subicular 
neurons that may be consistent with defects in 1-mediated cell-cell adhesion (Wimmer 
et al., 2010; Reid et al., 2014). While multiple in vitro studies have demonstrated β1-
C121W polypeptide expression at the surface of heterologous cells in which 1-C121W 
cDNA was overexpressed (Tammaro et al., 2002; Meadows et al., 2002; Patino et al., 
2011), viral transduction of mouse neurons predicted that β1-C121W may be retained 
inside the cell and thus non-functional (Wimmer et al., 2010).  Finally, studies of 
homozygous Scn1bW/W knock-in mice, which model the epileptic encephalopathy Dravet 
syndrome, showed that 1-C121W subunits fail to localize to axon initial segments (AIS) 
of subicular neurons, however, this study did not address whether these mutant 1 
polypeptides are expressed at the neuronal cell surface (Wimmer et al., 2015). 
Here, we compared Scn1b-C121W knock-in GEFS+ mice (Scn1b+/W) (Wimmer et al., 
2010) with mice expressing the Scn1b null allele, Scn1b+/- mice (Chen et al., 2004), to 
ask whether the β1-C121W GEFS+ mutation results in simple loss-of-function or 
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whether it conveys a deleterious gain-of-function. The parents of a Dravet syndrome 
patient homozygous for the loss-of-function mutation SCN1B-R125C, who are each 
heterozygous for the mutation, did not report seizures (Patino et al., 2009). 
Furthermore, the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org/) 
database reports several neurologically normal patients with predicted heterozygous 
loss-of-function SCN1B mutations, suggesting that SCN1B haploinsufficiency may be 
tolerated. Here, we report that the thermal seizure phenotype of Scn1b+/W GEFS+ mice 
is more severe than that of Scn1b+/- mice. 1-C121W polypeptides are expressed at the 
cell surface of cultured Scn1bW/W mouse neurons, however, they are expressed at lower 
levels than 1-WT polypeptides in Scn1b+/+ brain. 1-C121W appears to be 
incompletely glycosylated compared to WT 1 polypeptides, and its association with 
VGSC  subunits is disrupted. 1-C121W subunits localize to neuronal cell bodies in 
Scn1bW/W mouse brain cortex and cerebellum, but, unlike WT 1 subunits, are not 
translocated to specialized axonal subcellular domains, including the AIS and nodes of 
Ranvier. Taken together, our results suggest that the Scn1b-C121W GEFS+ mutation 
confers deleterious gain-of-function effects in vivo.  
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Methods 
Mice 
Scn1b+/-, Scn1b-/-, Scn1b+/W and Scn1bw/w mice of both genders were generated from 
Scn1b+/- and Scn1b+/W mice as previously described (Chen et al., 2004; Wimmer et al., 
2010). Scn1b+/- mice were >N20 on the C57BL/6J background strain. Scn1b+/W mice 
were generated using C57BL/6J mouse embryonic stem cells and maintained on the 
C57BL/6J strain for >5 generations. Thus, Scn1b+/+ mice from Scn1b+/W x Scn1b+/W 
crossings are congenic C57BL/6J. In spite of this, to be confident that there were no 
background differences, we compared Scn1b+/+ mice from Scn1b+/W x Scn1b+/W litters 
and Scn1b+/- x Scn1b+/-W litters in all experiments. No significant differences were 
observed between Scn1b+/+ mice generated from either line. Animals were housed in 
the Unit for Laboratory Animal Medicine at the University of Michigan. All procedures 
were approved by the University of Michigan Committee on Use and Care of Animals. 
Thermal Seizures 
Mice were tested for thermal seizure susceptibility at four developmental ages: 
postnatal day (P)15, P16, P20-21, and P30-33. Seizures were classified according to a 
modified Racine scale, as reported previously (Racine, 1972; Patino et al., 2009). The 
scale is as follows: 0, no response; 1, staring or unresponsive; 2, focal or clonic 
convulsion involving twitches or myoclonic jerk of a single limb, head nods or backing; 
3, clonus of both forelimbs; 4, rearing/uncontrolled hind limbs, without loss of posture; 5, 
loss of upright posture, usually preceded by jumping/rearing; 6, prolonged convulsion (≥ 
30 sec of tonic/clonic convulsions with loss of posture) or death. Due to the difficulty in 
accurately observing level 1 seizures without an EEG, seizures rated as level 1 were 
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not recorded. Therefore, all seizures used in this analysis were of level 2 or greater. 
Following a 1 ml intraperitoneal (IP) injection of 0.9% NaCl to prevent dehydration, a 
rectal thermometer was positioned to monitor body temperature (BT). A heat lamp, 
connected to the monitor, controlled BT according to the following protocol. Mice were 
acclimated with set temperature (ST) at 37°C for 30 min. Then, during the observation 
period, ST was increased by 0.5°C every 2 min. At the 20 min time point, ST was held 
at 42.5°C for an additional 15 min. When a seizure was observed, the following were 
recorded: BT, seizure severity (Racine scale), and time elapsed from the beginning of 
the observation period. After the experiment, all animals were euthanized followed by 
removal of vital organs. Genotypes were blinded to the observer and experiments were 
gender-balanced. No significant differences were noted between female and male 
animals. WT animals from Scn1b+/- and Scn1b+/W litters were considered separate 
groups and compared directly during analysis. However, no significant differences were 
observed between WT genotypes and thus these animals were pooled for final analysis. 
The numbers of mice used for P15, P16, P20-21, and P30-33 age groups were: 
Scn1b+/+ (22, 24, 20, 25); Scn1b+/- (16, 16, 18, 23); Scn1b+/W (16, 11, 11, 17), 
respectively. 
Behavioral Seizure Analysis 
For hyperthermia-induced seizure studies, time and temperature to first seizure were 
analyzed using the Mantel-Cox test. The most severe seizure for each mouse was 
analyzed using the Kruskal-Wallis test. Mann-Whitney analysis of these data gave 
similar results. For all analyses, P ≤ 0.05 was the threshold for significance. P-values 
from all analyses are listed in Table 2.1.  
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Antibodies 
Primary antibodies were as follows: rabbit anti-Scn1b (directed against an intracellular 
1 epitope, Cell Signaling Technology, pre-production serum of D4Z2N, cat #14684, 
1:3000 used for Western blotting); rabbit anti-Scn1b (directed against an extracellular 
1 epitope, Cell Signaling Technology, pre-production serum of D9T5B, cat #13950, 
1:25 used for immunofluorescence in optic nerves); rabbit anti-Scn1b (directed against 
an extracellular 1 epitope, Cell Signaling Technology, production version of D9T5B, cat 
#13950, 1:250 used for immunofluorescence in brains); guinea pig anti-Caspr (gift from 
Dr. James Salzer, New York University School of Medicine, 1:1000 used for 
immunofluorescence in optic nerves); mouse anti-PAN VGSC α-subunit (Sigma, S8809, 
1:200 used for immunofluorescence in optic nerves and co-immunoprecipitation); goat 
anti-ankyrinG (recognizing total ankyrinG, gift from Dr. Vann Bennett (He et al., 2014; 
Jenkins et al., 2015), 1:500 used for immunofluorescence in brains); mouse anti-
calbindin (Sigma, C9848, 1:400 used for immunofluorescence in brains); rat anti-Ctip2 
(Abcam, ab18465, 1:400 used for immunofluorescence in brains); rabbit anti-PAN 
VGSC α-subunit (Cell Signaling Technology, D2I9C, 1:1000 used for Western blotting); 
mouse anti-human α-tubulin (Cedarlane Laboratories, Hornby, ON; CLT9002; 1:5000, 
used for Western blotting); mouse anti-HSP90 (Enzo Life Sciences, AC88, 1:1000, used 
for Western blotting). Secondary antibodies for Western blotting were as follows: HRP-
conjugated goat anti-mouse (1:500, Thermo Fisher Scientific), HRP-conjugated goat 
anti-rabbit (1:500, Thermo Fisher Scientific). Secondary antibodies from Thermo Fisher 
Scientific, used for immunofluorescence at a 1:500 dilution, were as follows: 
AlexaFluor® goat anti-rabbit 488nm, AlexaFluor® goat anti-mouse 594nm, AlexaFluor® 
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goat anti-guinea pig 647nm, AlexaFluor® donkey anti-rabbit 488nm, AlexaFluor® 
donkey anti-goat 594nm, AlexaFluor® donkey anti-rat 594nm, and AlexaFluor® donkey 
anti-mouse 647nm. 
Mouse brain membrane preparation 
Mouse brain membrane proteins were prepared as described (Isom et al., 1995a). 
Complete Protease Inhibitors (Roche Diagnostics) were added to all solutions at 2 times 
the recommended concentration to minimize protein degradation. Briefly, immediately 
following anesthetization of the animal by isoflurane, brains were dissected and 
homogenized in ice-cold Tris EGTA (50 mM Tris, 10 mM EGTA, pH 8.0). A polytron 
homogenizer was used to mechanically shear the tissue, followed by 20 strokes of 
homogenization in a chilled glass homogenizer. Homogenates were centrifuged at 2500 
x g for 20 min at 4˚C in a swinging bucket rotor to separate homogenized proteins from 
cell debris and nuclei. The supernatant was then ultracentrifuged (Thermo Fisher 
Scientific, Sorval WX Ultra 80 ultracentrifuge) at 148,000 x g for 55 min at 4oC in a fixed-
angle rotor (Thermo Fisher, TFT-80.4). The final pellet was resuspended in ice-cold 
Tris-EGTA and analyzed for protein concentration using the BCA Assay (Thermo Fisher 
Scientific). Protein sample aliquots were stored at -80˚C. 
Western blot analysis 
Western blots were performed as described (Malhotra et al., 2000). SDS sample buffer 
(final concentration 62 mM Tris-HCl, 10% glycerol, 34 mM SDS, 20 mM dithiothreitol, 
5% β-mercaptoethanol) was added to protein samples prior to separating on SDS-
PAGE gels. Hand-poured 10%, 12%, 15%, and pre-poured 4-15% (Bio-Rad) SDS-
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PAGE gels were used as indicated in figure legends. With the exception of experiments 
using the mouse anti-HSP90 antibody, Western blots were performed using blocking 
solution containing 5% non-fat dry milk and 1% bovine serum albumin in TBST (0.1 M 
Tris-Cl, 0.5 M NaCl, pH 7.5, 0.1% Triton X-100), with primary antibodies incubated 
overnight at 4oC. For experiments using the mouse anti-HSP90 antibody, a blocking 
solution of 2% non-fat dry milk in TBST was used and primary antibody was incubated 
overnight at RT. All secondary antibodies were applied for 1 h at RT. West Femto or 
West Dura reagent (Thermo Fisher Scientific, 34095 or 34076) was used for detection. 
Immunoreactive signals were recorded using a Leica Odyssey Fc Imager. 
Coimmunoprecipitation 
For co-immunoprecipitation experiments, 200 μl of protein-G Sepharose beads (Sigma-
Aldrich) were washed three times in PBS and divided equally into 4 microcentrifuge 
tubes. Beads were incubated overnight with end-over-end mixing at 4oC with 250 μl of 
dilution buffer (60 mM Tris/HCl, pH 7.5; 180 mM NaCl; 1.25% Triton X-100; 6 mM 
EDTA) and 5 μg mouse anti-PAN VGSC antibody (Sigma) or 1.2 μg of mouse IgG 
(Jackson Immuno Research). Freshly-thawed mouse brain membrane protein 
preparations (~1.2 mg of Scn1b+/+ or Scn1bW/W for Figure 2.4 A; ~1.2 mg of Scn1b+/+ or 
~2.4 mg of Scn1bW/W for Figure 2.4 B) were resuspended in dilution buffer (with 
Complete Protease Inhibitors at 2X of the recommended concentration) to a 
concentration of ~2.4 mg/mL. Protein samples were centrifuged at 5000 x g for 5 min. 
To remove proteins that non-specifically associate with the Sepharose beads, protein 
supernatants were pre-cleared by incubation with 50 μl protein-G Sepharose beads 
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(washed three times in PBS, but not incubated with antibody or IgG) for 1 hr at 4oC with 
end-over-end mixing. The Sepharose beads were pelleted by centrifugation at 3000 x g 
for 3 min. Protein supernatant was removed and added to protein-G Sepharose beads 
previously incubated overnight with antibody or IgG. The protein and beads were 
incubated at 4oC for 4 h with end-over-end mixing. Beads were washed three times with 
ice-cold wash buffer (50 mM Tris/HCl, pH 7.5; 150 mM NaCl; 0.02% SDS; 5 mM EDTA; 
2X Complete Protease Inhibitors) with 0.1% Triton X-100, and then washed once with 
wash buffer without 0.1% Triton X-100. 25 μl of Western blot sample buffer (see 
Western blot Methods) was added to beads and heated for 10 min at 85oC to elute 
proteins from the beads. 
Quantification of β1 immunoreactive bands 
Quantification of β1 immunoreactive bands on Western blots was performed using 
ImageJ (version 1.49, Wayne Rasband, NIH). Tissues from 4 animals from each 
genotype were tested in three replicate experiments. Values were normalized for protein 
loading using α-tubulin. Protein levels for each experiment were normalized to the mean 
for Scn1b+/+. Final analysis was performed using a two-way ANOVA.  
PNGaseF digestion 
PNGaseF digestion of Scn1b+/+ and Scn1bW/W mouse brain membrane proteins was 
performed as recommended by the manufacturer (New England BioLabs) with the 
following changes: Frozen brain membrane protein samples were thawed on ice, 100 
μg of protein with 1X Glycoprotein Denaturing Buffer (NEB) in a total volume of 15.6 μl 
was heated for 10 min at 85oC. Then 2.4 μl G7 buffer (NEB), 2.4 μl NP40 (NEB), and 
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3.6 μl PNGaseF (or ddH2O for mock digestion) were added for a total volume of 24 μl. 
Reactions were incubated at 37oC for 2 h. Western sample buffer was added to each 
sample and samples were separated by SDS PAGE followed by Western blot. For 
Western blots, 100 μg of untreated brain membrane protein were loaded as ‘input’ 
controls. 
Primary Culture of Cortical Neurons 
P0-P1 mouse cortices were isolated and digested in unsupplemented Neurobasal 
medium (Gibco) with 0.25% trypsin for 15 min at 37°C. Cortices were then washed in 
Hanks Buffered Salt Solution (Gibco) and cells dispersed with fire polished Pasteur 
pipets. Cells were purified on a 35%/25%/20%/15% Optiprep (Axis-Shield) density 
gradient. The bottom 2 fractions were collected, washed, and diluted with Neurobasal 
medium supplemented with 0.5 mM L-glutamine (Gibco), 1% penicillin/streptomycin 
(Gibco), and 2% B-27 supplement (Gibco). 200 µl of cells were plated on 15 mm 
diameter poly-d-lysine pre-coated coverslips (Neuvitro) at a density of 250,000 
cells/coverslip. After 24 h in a 37°C humidified 5% CO2 incubator, 2 ml of the above 
supplemented Neurobasal medium were added. 50% of the medium was replaced 
every 3rd day and cells were used on the 16th day in vitro (DIV). 
Surface Biotinylation 
Surface biotinylation of primary cultured neurons was performed using the Cell Surface 
Protein Isolation kit (Thermo Fisher Scientific 89881), with adaptations to the 
manufacturer’s suggested protocol as follows. All solutions were provided in the kit and 
reactions were performed on ice unless otherwise indicated. Briefly, primary neurons, 
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cultured as described above, were plated on coverslips and cultured in 6-well plates, 
with each well containing one coverslip. The culture medium was removed and cells 
were gently washed twice with ice-cold PBS. 1.5 ml of 0.25 mg/mL Sulfo-NHS-SS-Biotin 
in ice-cold PBS was added to each well. Plates were rocked gently at 4oC for 30 min to 
ensure even coverage of the cells with the labeling solution. 150 μl of Quenching 
solution was added to each well and plates were rocked at RT for 5 min. Contents of 
each well were then scraped and transferred to 50 mL conical tubes. Each well was 
washed with 1 ml TBS and wash was added to the corresponding tube of cells. Cells 
were pelleted at 1000 x g for 10 min in a swinging bucket rotor. The pellet was washed 
gently with 5 ml of TBS and then re-pelleted. From this point, Complete Protease 
Inhibitors (Roche Diagnostics) were added to all solutions at 2 times the recommended 
concentration to minimize protein degradation. Cells were resuspended in 25-50 μl of 
lysis buffer. Cell lysates were stored at -80˚C. After 4-5 rounds of culture and 
biotinylation, cell lyses from the same genotypes were thawed on ice and pooled to 
achieve sufficient protein for detection. Pooled cell lysates were sonicated with a pulse 
sonicator at 20% power every 5 min on ice for 30 min. Cell lysates were spun at 10,000 
x g for 2 min to remove cellular debris. 20 μl of each supernatant was saved for ‘total 
cell lysate’ sample analysis and used to determine protein concentration. For Figure 2.3, 
~40 ug of protein was loaded in the total cell lysate lanes. The remaining supernatant 
(~450 ug of protein per sample) was added to 100 μl washed NeutrAvidin Agarose 
beads and rotated end-over-end overnight at 4oC. The following day, beads were 
washed 3x for 5 min at 4oC with 500 μl ice-cold wash buffer. Beads were then rotated 
for 1 h at RT with 25 μl of sample buffer containing 50 mM DTT to ensure complete 
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elution. The entire sample for each genotype was loaded and designated as ‘surface 
proteins’ for Figure 2.3. 
Immunohistochemistry 
P15 littermates of the indicated genotypes were anesthetized using isofluorane. Mice 
were cardioperfused with ~10 ml PBS followed by ~10 ml 4% paraformaldehyde (PFA). 
Tissues were post-fixed (brains overnight, optic nerves for 15 min) in 4% PFA. Tissues 
were then cryoprotected in 10% sucrose followed by 30% sucrose overnight, flash 
frozen in 2-methylbutanol, and stored at -80˚C. Optic nerves were embedded in O.C.T. 
(Tissue-Tek) prior to freezing. Longitudinal 10 μm optic nerve sections and 20 μm 
coronal brain sections were cut on a Leica cryostat and stored at -20˚C until processing 
for immunohistochemistry. 
For immunohistochemistry, sections were dried and post-fixed for 10 min with 4% PFA, 
washed 3 times for 5 min each with 0.05 M phosphate buffer (PB), incubated in blocking 
buffer (10% goat or donkey serum as appropriate, 0.3% Triton X-100, 0.1% PB) for ≥ 2 
h in a humidified chamber. Brain sections were incubated with 1% SDS in PB for 5 min 
prior to washing steps. Sections were then incubated with primary antibodies (diluted in 
blocking buffer) overnight in a humidified chamber and washed 3 times for 10 min with 
0.1% PB. From this point all steps were performed in the dark to minimize 
photobleaching of secondary antibodies. Sections were incubated with AlexaFluor-
conjugated secondary antibodies (diluted in blocking buffer) for 2 h, washed 3 times for 
10 min in 0.1% PB, dried, and coverslips were mounted using ProLong Gold anti-fade 
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reagent (Life Technologies). Finally, brain sections were incubated with DAPI for 20 min 
before mounting.  
Sections were imaged using a Nikon A1R confocal microscope with Nikon NIS-
Elements AR software located in the University of Michigan Department of 
Pharmacology using either a 60x NA 1.40 oil objective or a 20x NA 0.75 dry objective. 
Optic nerve sections were imaged using 3.1x digital zoom and Nyquist settings. All 
other settings were identical for all sections imaged in each experiment. For each optic 
nerve section, ≥3 single-section images were taken for analysis. Confocal images 
spanning 3 μm were acquired at 0.15 μm intervals and flattened using maximal signal 
for presentation in Figure 2.5. Images were analyzed as described below. Cortical and 
cerebellar confocal images spanning 10 m were acquired at 0.175 m intervals (for 
60x) or 1.1 m intervals (for 20x) and flattened using maximum signal for presentation in 
Figures 2.6 and 2.7. 
Quantification of β1 immunofluorescence 
For node of Ranvier studies, optic nerves from 4-6 animals per genotype were 
analyzed. Each animal was stained in at least 3 of 4 total independent 
immunohistochemistry experiments, with at least 2 sections (4 optic nerves) per animal 
used in each experiment. Using NIS-Elements Advanced Research software (Nikon), 
the “region of interest” function was used to outline the area of each complete node in 
each image. In this step, only anti-PAN VGSC and anti-Caspr signals were made 
visible, thus blinding the observer to the anti-β1 signal. The software was then used to 
quantify the average anti-β1 and anti-PAN VGSC signal intensities for each region of 
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interest. To remove nodes that were out of the plane of focus, nodes with the lowest 
20% of anti-PAN VGSC signal were discarded prior to analysis. The average anti-β1 
signal intensity per node for each optic nerve sample was used in final analysis (4 optic 
nerves per animal, per experiment). These values were normalized by setting the mean 
of all WT animals and the mean for all KO animals for the experiment to 1 and 0, 
respectively, using the “normalize” function in GraphPad Prism. Normalized values were 
analyzed using a Linear Mixed Model analysis performed using SPSS Statistics 
software (IBM) to account for variation between experiments as well as for variation 
between genotypes. The four comparisons indicated in Figure 2.5 B were determined 
using this analysis and then correcting for multiple comparisons by multiplying each p-
value by the number of comparisons.  
For AIS experiments, 3-4 animals per genotype were used, and 2-3 brain sections per 
animal per region were imaged for analysis. In all cases, sections obtained from the 
same locations relative to Bregma were chosen.  For cortex, imaging was done in the 
same region in both layer 2/3 and layer 5/6 of the somatosensory cortex, with one 
image per section per region for each animal.  For cerebellum, 3 images per section for 
each animal were obtained from the same regions of the simple lobule of the 
cerebellum.  Images were imported into NIH ImageJ using the BioFormats plugin and 
flattened as described above. For each image, AISs were first identified as regions of 
linear ankyrinG immunolabeling and then evaluated for coincident linear 1 
immunolabeling using the Colocalization Finder plugin for ImageJ, followed by visual 
reassessment of each identified AIS for confirmation.  AISs positive for 1 were counted 
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and results expressed as percent of positive AISs per field of view. Due to unequal 
number of animals per genotype, statistical Analysis of Variance was not appropriate. 
Therefore the percent of positive AISs per field of view was analyzed using a Linear 
Mixed Model Analysis performed using SPSS Statistics software (IBM). P-values were 
corrected for multiple comparisons by multiplying by the number of comparisons. 
Statistics 
All statistical analyses were performed using GraphPad Prism, unless otherwise 
indicated, with significance defined as P < 0.05. 
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Results 
Scn1b+/W mice are more susceptible to thermal seizures than Scn1b+/- mice 
To ask whether the SCN1B-C121W GEFS+ mutation results in simple loss-of-function 
or whether it confers a deleterious gain-of-function in vivo, we compared mice 
expressing the Scn1b null allele (Chen et al., 2004) with mice expressing the human 
SCN1B-C121W GEFS+ knockin allele (Wimmer et al., 2010), both congenic on the 
C57Bl/6 strain. Throughout the manuscript, the heterozygous and homozygous animals 
from these strains are indicated as Scn1b+/-, Scn1b-/-, Scn1b+/W, and Scn1bW/W, 
respectively. Previous work has shown that Scn1b+/W GEFS+ mice seize at lower body 
temperatures than their WT littermates (Wimmer et al., 2010). We compared the 
thermal seizure susceptibility of the two mouse lines at time points between postnatal 
day (P)15 and 33 (P15, P16, P20-21, and P30-33) using a previously published protocol 
(Oakley et al., 2009). To evaluate potential genetic background effects between models, 
we tested WT littermates from both mouse lines for all thermal seizure, protein analysis, 
and immunostaining experiments presented in the manuscript. We observed no 
significant differences between Scn1b+/+ mice derived from Scn1b+/- x Scn1b+/- litters, 
and Scn1b+/+ mice derived from Scn1b+/W x Scn1b+/W litters. Thus, for analyses 
presented in the manuscript, results from these two WT groups were pooled, allowing a 
direct comparison of Scn1b+/W with Scn1b+/- mice. Overall, for both genotypes, younger 
mice had more severe seizures, seized at lower body temperatures, and had a shorter 
latency to first seizure compared to older mice of the same genotype (Figure 2.1 A, 
Table 2.1), suggesting that seizure susceptibility using this model is age-dependent, 
similar to other models of pediatric febrile seizures (Oakley et al., 2009). 
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Figure 2.1 Scn1b+/W GEFS+ mice are more susceptible to heat-induced seizures 
than Scn1b+/- and Scn1b+/+ mice.  
Behavioral seizures were observed by an investigator blinded to genotype while using a 
heat lamp to incrementally increase body temperature. A. Seizure severity recorded for 
each animal, measured according to the modified Racine scale (mean ±SEM). 
Genotypes were compared at the same age. (Kruskal-Wallis; P<0.001, Scn1b+/W vs. 
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Scn1b+/+; P<0.05 Scn1b+/W versus Scn1b+/-). B. Histogram of the most severe seizures 
at P15 showing that 75% of Scn1b+/W GEFS+ mice experienced a seizure of Racine 
score 6, compared with 25% or 50% of Scn1b+/+ or Scn1b+/-, respectively. C - E. 
Survival curves to first observed seizure for P15 (C, E) and P16 (D) mice in relation to 
time (C, D) or body temperature (E). C.  At P15, Scn1b+/W GEFS+ mice experienced 
seizures sooner in the observation period than the other genotypes (Mantel-Cox; 
P<0.0001, Scn1b+/W versus Scn1b+/+; P<0.0001, Scn1b+/W versus Scn1b+/- mice). D. The 
difference in C was not observed at P16. E.  Scn1b+/W GEFS+ mice seized at lower 
body temperatures than Scn1b+/+ or Scn1b+/- mice (Mantel-Cox; P<0.0001, P<0.01, 
respectively). Number of animals for P15, P16, P20-21, and P30-33 groups were: 
Scn1b+/+ (22, 24, 20, 25), Scn1b+/- (16, 16, 18, 23), Scn1b+/W (16, 11, 11, 17), 
respectively. 
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Time to First Seizure WT +/- C/W WT vs +/- WT vs. CW CW vs. +/-
P15 20.6' 20.91' 16.69' 0.605 ****<0.0001 ****<0.0001
P16 22.18' 21.45' 21.37' 0.5785 0.9288 0.583
P15 vs. P16 P-value 0.3877 0.4453 ***0.0004
P20-21 undefined undefined 26.05'
P30-33 undefined undefined undefined
Temp (˚C) at First Seizure
P15 42.3 >42.5 41.5 0.7113 **0.0022 ***0.0001
P16 42.55 42.6 42.5 0.199 0.6065 0.1677
P15 vs. P16 P-value 0.2643 0.7768 *0.019
P20-21 >42.5 >42.5 >42.5
P30-33 >42.5 >42.5 >42.5
Most Severe Seizure
P15 3.45±0.40 (22) 4.313±0.35 (16) 5.250±0.28 (16) ns ** ns
P16 2.75±0.42 (24) 3.25±0.42 (11) 3.00±0.77 (16)
P20-21 1.70±0.53 (20) 2.211±0.60 (19) 2.545±0.77 (11)
P30-33 1.042±0.34 (25) 2.846±0.78 (23) 2.286±0.69 (17)
P-values
Median Survival
Mantel-Cox
Median Survival
0.3818
0.3101
0.5851
Mean +/- SD (n)
Mantel-Cox
0.4667
Median Survival
Median Survival
Kruskal-Wallis
ns
ns
ns  
Table 2.1 Statistical values for thermal seizure experiments.  
Time and temperature to first seizure comparisons were made using Mann Whitney Comparison, median survival is given. 
For most severe seizure, mean ±SD is given. For the P20-21 and P30-33 groups, there is no significant difference 
between all groups for temperature to first seizure (P=0.3574, 0.1518) or time to first seizure (P=0.6382, 0.2517). All 
groups have >11 mice, see methods for descriptions of statistical analysis. 
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We observed a significant difference in seizure phenotype between Scn1b+/W GEFS+ 
and Scn1b+/- mice at P15. At this time point, Scn1b+/W mice seized more severely than 
either WT or Scn1b+/- mice (P = 0.0141, 0.0443, respectively; Figure 2.1 A,B). 75% of 
Scn1b+/W GEFS+ mice experienced prolonged convulsions (with or without death) 
during the experimental period (recorded as Racine score 6) compared to 50% of 
Scn1b+/- mice and 25% of Scn1b+/+ mice (Figure 2.1 B). Furthermore, latency to first 
seizure and body temperature at first seizure, as represented by time-to-event curves, 
were both significantly reduced in Scn1b+/W GEFS+ mice compared to Scn1b+/- mice 
(P<0.0001, 0.01, respectively; Figure 2.1 C and E). Taken together, these data indicate 
that Scn1b+/W GEFS+ mice, but not Scn1b+/- mice, are significantly more susceptible to 
heat-induced seizures than WT. In comparison, at P16 and at older ages (P20-21 and 
P30-33), there were no significant differences in any thermal seizure parameters 
between Scn1b+/W, Scn1b+/-, or Scn1b+/+ mice (Figure 2.1 A and D, Table 2.1). As 
discussed above, it is unlikely that the observed differences between Scn1b+/W and 
Scn1b+/- mice are the result of residual genetic background differences between the 
mouse lines. The observation that Scn1b+/W GEFS+ and Scn1b+/- mice are different in 
terms of thermal seizure susceptibility is strong evidence that the human SCN1B-
C121W GEFS+ mutation is not a simple, loss-of-function allele and suggests instead 
that it confers a deleterious gain-of-function. 
β1-C121W protein is expressed at lower levels in brain and may be incompletely 
glycosylated compared to WT 
We next compared levels of β1-WT and β1-C121W polypeptide expression in brain 
membrane preparations from Scn1b+/+ and Scn1bW/W mice, respectively. Separation of   
70 
 
 
Figure 2.2 Comparison of β1-C121W and β1-WT protein expression.  
Representative Western blots comparing β1 immunoreactivity in Scn1b+/+ and Scn1bW/W 
mouse brain membrane preparations. β1-C121W polypeptides migrate at a lower 
apparent molecular weight than β1-WT separated on a 10% SDS-PAGE gel. 
Immunoreactive bands were quantified using densitometry. Each band density was first 
normalized to its corresponding α-tubulin signal, and β1 levels in Scn1bW/W mice were 
expressed as a percentage of β1 in Scn1b+/+ mice. Scn1bW/W mice had 45±10% of 
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Scn1b+/+ β1 expression (two-way ANOVA; P = 0.0001; three replicate experiments with 
4 animals of each genotype). B. Representative Western blots showing mock digested, 
PNGaseF digested, and control brain membrane inputs from Scn1b+/+ and Scn1bW/W 
brain separated on a 12% SDS-PAGE gel. β1-WT and β1-C121W polypeptides migrate 
at similar molecular weights following removal of N-linked glycosylation by PNGaseF 
(N=3). C.  Representative Western blots, separated on a 15% SDS-PAGE gel, 
comparing levels of β1-WT and β1-C121W polypeptides in P14-15, P17, and >20wk old 
Scn1b+/+, Scn1b+/W, and Scn1bW/W mice. α-tubulin is shown as a loading control. Every 
Scn1bW/W mouse tested showed the lower molecular band only (P14-15, N=5; P17, 
N=5). Every Scn1b+/W sample tested showed both bands (P14-15, N=11; P17, N=6; >20 
wks, N=4). 
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equivalent amounts of total protein on 10% SDS-PAGE gels followed by Western 
blotting with anti-1 antibody showed that the level of β1-C121W expression in brain 
was approximately 50% of β1-WT (Figure 2.2 A). In addition, the β1-C121W 
immunoreactive band migrated at a lower apparent molecular weight compared to β1-
WT (Figure 2.2 A). This molecular weight difference was not observed in our previous 
heterologous expression studies (Meadows et al., 2002) and thus may be tissue or 
species specific. PNGaseF digestion of brain membrane preparations prior to SDS-
PAGE analysis, to remove N-linked glycosylation, abrogated this apparent molecular 
weight difference (Figure 2.2 B), suggesting differences in post-translational 
modification between β1-WT and β1-C121W proteins in brain in vivo. Finally, the 
absence of anti-1 immunoreactive signal in the Scn1b-/- lane confirmed antibody 
specificity (Figure 2.2 A). 
Because aberrant post-translational modification can alter protein targeting for 
degradation (Ellgaard and Helenius, 2003), we tested brain membrane preparations 
from mice at different ages for the presence of the β1-C121W lower molecular weight 
band. SDS-PAGE analysis of β1 polypeptides from Scn1b+/+, Scn1b+/W, and Scn1bW/W 
mice showed evidence for β1-C121W expression in all mice tested, even at > 20 weeks 
of age (Figure 2.2 C). Thus, β1-C121W polypeptide expression is maintained 
throughout mouse brain development and does not appear to decrease with age. 
β1-C121W polypeptides localize to the neuronal cell surface in vivo 
Cell surface expression is required for VGSC subunit function. Although viral expression 
of a GFP-tagged 1-C121W construct in mouse neurons predicted intracellular retention 
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(Wimmer et al., 2010), other studies of β1-C121W heterologous expression showed cell 
surface localization (Meadows et al., 2002; Patino et al., 2011). In addition, 
heterologous co-expression studies of β1-C121W and VGSC α subunits reported 
increased channel expression at the cell surface and/or increased sodium current 
compared to  subunits alone, predicting that β1-C121W localizes to the cell surface 
and retains the channel chaperone functions of β1 (Tammaro et al., 2002; Meadows et 
al., 2002; Rusconi et al., 2007; Baroni et al., 2013). To determine whether β1-C121W 
localizes to the cell surface of neurons in vivo, we performed surface biotinylation of 
cultured Scn1b+/+ and Scn1bW/W cortical neurons. We detected β1 and 1-C121W 
polypeptides in both total cell lysate and biotinylated cell surface protein samples from 
Scn1b+/+ and Scn1bW/W neurons, respectively (Figure 2.3). As a control, the cytosolic 
protein, HSP90, was detected in the cell lysate but not in the biotinylated samples, 
confirming the enrichment of cell surface proteins in the biotinylated fraction. These data 
suggest that endogenously expressed β1-C121W polypeptides are localized to the cell 
surface of cortical neurons in vivo. 
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Figure 2.3 β1-WT and β1-C121W are expressed at the neuronal cell surface in 
cultured mouse cortical neurons.  
Primary cortical neurons were cultured from Scn1b+/+ and Scn1bW/W mice. At 16 DIV, 
surface proteins were labeled with biotin as described in Methods. An aliquot of total cell 
lysate was reserved prior to performing immunoprecipitation with streptavidin beads to 
enrich for cell surface proteins. Total cell lysate for Scn1b+/+ and Scn1bW/W, along with 
control brain membrane samples were separated on a 10% SDS-PAGE gel and 
immunoblotted with anti-β1 and anti-HSP90 antibodies. Anti-HSP90 immunoreactivity 
was used as an internal control to ensure enrichment of surface proteins in the 
biotinylated fraction. N=2 
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β1-C121W association with VGSC α-subunits is not detectable 
A critical role for β1 subunits in brain is sodium current modulation via association with 
VGSC α-subunits (Chen et al., 2004; Brackenbury et al., 2010). Previous studies 
showed that overexpressed, recombinant β1-C121W protein could be co-
immunoprecipitated with Nav1.1, Nav1.2, or Nav1.3 α-subunits from solubilized, 
transfected cell lines (Meadows et al., 2002; Aman et al., 2009). However, these results 
may not reflect in vivo association of these subunits due to artifacts of heterologous 
overexpression. We therefore performed co-immunoprecipitation assays from mouse 
brain membrane preparations using anti-PAN-VGSC antibody followed by anti-1 
antibody to assess -1 association.  We detected 1 but not 1-C121W 
association in these samples, suggesting that β1-C121W does not associate with brain 
VGSC subunits in vivo (Figure 2.4 A). Because the level of β1-C121W polypeptide 
expression is approximately 50% of the level of 1-WT in mouse brain (Figure 2.2 A), 
we repeated the co-immunoprecipitation experiment using twice the amount of 
Scn1bW/W starting material. In spite of this increase, we did not detect β1-C121W and 
VGSC α-subunit association by co-immunoprecipitation (Figure 2.4 B). Thus, while the 
Scn1b-C121W mutation does not affect β1 cell surface expression in vivo, it does 
appear to weaken or disrupt VGSC α-β1 association. 
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Figure 2.4 β1-C121W association with VGSC α-subunits is not detectable. 
Brain membrane proteins from P15 Scn1b+/+ and Scn1bW/W animals were 
immunoprecipitated (IP) with either mouse IgG or mouse antibody against PAN VGSC α 
subunit. Input samples, IP samples for each genotype, and a control Scn1b-/- membrane 
sample were separated on a 4-15% SDS-PAGE gel and immunoblotted with rabbit anti-
PAN VGSC and anti-β1 antibodies. A. Representative Western blot of PAN VGSC-β1 
co-immunoprecipitation using equivalent amounts of membrane proteins for each 
genotype. N=3. B. Representative Western blot of PAN VGSC-β1 co-
immunoprecipitation using twice as much Scn1bW/W as Scn1b+/+ membrane protein, to 
have equivalent amounts of β1 protein in the samples (see Figure 2.2). Input samples 
were loaded in the same ratio to reflect the difference in starting protein. N=1.  
77 
 
β1-C121W polypeptides differentially localize to neuronal subcellular domains 
VGSC 1 subunits co-localize with VGSC  subunits at the AIS and nodes of Ranvier in 
vivo (Chen et al., 2004; Brackenbury et al., 2010; Wimmer et al., 2015). β1-mediated 
cell adhesive interactions may be particularly important at the nodes of Ranvier, as 
Scn1b null mice exhibit dysmyelination, reduced numbers of nodes, and disruption of 
axo-glial cell-cell contact in a subset of neurons (Chen et al., 2004). Thus, we asked 
whether β1-C121W is localized to these axonal subcellular domains in vivo.  
We performed fluorescence immunohistochemistry of longitudinally sectioned WT and 
mutant mouse optic nerve. We found the level of β1 immunofluorescence was 
significantly decreased at nodes of Ranvier in Scn1bW/W mice compared to WT, and 
similar to that observed in Scn1b-/- mice (Figure 2.5 A and B). Quantification of anti-1 
optic nerve nodal immunofluorescence signal across genotypes showed that Scn1b+/W 
levels were lower than Scn1b+/+, but higher than Scn1b+/- (Figure 2.5 B).  
We next examined 1-WT and 1-C121W immunofluorescence localization to the AIS 
in multiple brain regions. Anti-β1 immunofluorescence staining revealed a high 
percentage of 1 positive AIS domains in cortical layer II and VI neurons and in 
cerebellar Purkinje neurons in Scn1b+/+, Scn1b+/-, and Scn1b+/W mice (Figure 2.6 A-C, J-
L, D-F). The anti-β1 antibody used for these experiments was directed against an 
extracellular Scn1b epitope and specifically detected both β1-WT and β1-C121W 
polypeptides on Western blots (Figure 2.6 Q). In Figure 2.6, the left micrograph in the 
panel for each cortical region is a merged image showing staining for the AIS marker   
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Figure 2.5 β1-C121W is not expressed at optic nerve nodes of Ranvier. 
A. Representative images showing that Scn1b+/W and Scn1b+/- mice have decreased 
anti-β1 immunofluorescence compared to WT. β1 immunofluorescence in Scn1bW/W 
optic nerve sections is not significantly different from Scn1b-/-. B. Quantification, as 
described in Methods, of anti-β1 immunofluorescence at optic nerve nodes of Ranvier. 
Data represent 4 independent immunohistochemistry experiments, with 4-6 animals per 
genotype in total. Each animal was tested in at least 3 experiments. Linear Mixed Model 
analysis was used to make comparisons between genotypes, see Methods for further 
details. Scale bar: 2 μm.  
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Figure 2.6 β1-C121W is not expressed at cerebellar or cortical axon initial 
segments. 
Representative confocal images of cortical layers II (A, D, G, J, M) and VI (B, E, H, K,  
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N) and Purkinje cells in the cerebellum (C, F, I, L, O) of Scn1b+/+ (A-C), Scn1b+/W (D-F), 
Scn1bW/W (G-I), Scn1b+/- (J-L), and Scn1b-/- (M-O) mice. For each genotype and cortical 
region, the left panel is a merged image of anti-ankyrinG (red), DAPI (blue), and anti-β1 
(green) staining; the middle panel is anti-β1 (white) staining; and the right panel is a 
higher magnification image of a single AIS with the merged image on the left and β1 
staining alone on the right. For cerebellum, merged images show anti-AnkG (red)/β1 
(green)/calbindin (magenta)/DAPI (blue) staining. Arrows (A, B, C, F) indicate examples 
of ankyrinG-positive, β1-positive AISs. Arrowheads (F, G, H, I) indicate examples of β1-
positive soma in Scn1b+/W and Scn1bW/W mice. Scn1bW/W and Scn1b-/- mice showed no 
β1 immunofluorescence at the AIS. Scale bars: large = 50 μm, small = 10 μm. Three 
mice of each genotype were tested. (P) Quantification of AISs positive for β1 
immunofluorescence. For all regions observed, Scn1bW/W mice were comparable to 
Scn1b-/- mice and had a >95% reduction in β1+ AISs compared to Scn1b+/+ mice 
(P<0.0001). In layer II and VI, Scn1b+/W mice had slightly fewer β1+ AISs compared to 
Scn1b+/+ and Scn1b+/- mice (layer II: 16.6±2.0%, P<0.0001, 14.0±2.3%, P<0.0001; layer 
VI: 3.7±0.8%, P<0.0001, 3.1±0.9%, P=0.007, respectively). (q) Western blot showing β1 
immunoreactivity in brain membranes from Scn1b+/+, Scn1bW/W, and Scn1b-/- mice using 
the D9T5B anti-β1 antibody used for immunofluorescence in Figure 2.6 and Figure 2.7. 
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ankyrinG (red, arrows in Figure 2.6 A and B), β1 (green), and DAPI (blue), the center 
micrograph shows anti-1 staining alone (white), and the right micrograph shows side-
by-side zoomed images of a single AIS showing merged anti-AnkG/β1/DAPI and anti-1 
staining, respectively. In panels showing cerebella, anti-calbindin staining (magenta) 
was used as a marker of Purkinje neurons, with the leftmost micrograph showing 
merged anti-AnkG (red, arrows in Figure 2.6 C and F)/β1 (green)/calbindin 
(magenta)/DAPI (blue) staining, followed by anti-β1 staining alone (white) and side-by-
side zoomed images of a single AIS showing merged anti-AnkG/β1/calbindin/DAPI and 
anti-β1 staining, respectively. In Scn1bW/W cortical and Purkinje neurons, anti-β1 
staining was observed at the soma (arrow heads) but not at the AIS (Figure 2.6 G-I). 
Both somal (arrowhead) and AIS (arrow) anti-β1 staining were observed in Scn1b+/W 
sections (Figure 2.6, D-F). These results suggest that mutant 1-C121W subunits do 
not prevent the translocation of WT 1 subunits to the axon. Anti-1 staining was absent 
in Scn1b-/- brain sections, as expected, demonstrating antibody specificity (Figure 2.6, 
M-O). Quantification showed an absence of β1-positive AISs in layer II, VI, and 
cerebellar Scn1bW/W sections compared to Scn1b+/+ and Scn1b+/W mice (Figure 2.6 P). 
There was also a slight, but significant, reduction in β1-positive AISs in layer II and VI 
Scn1b+/W sections compared to Scn1b+/+ and Scn1b+/-. Staining of cortical brain sections 
with a different anti-β1 antibody(Oyama et al., 2006) (used in (Wimmer et al., 2015)) 
also showed β1-positive AISs in Scn1b+/+ neurons in layers II and VI, similar to those in 
Figure 2.6 A-B (data not shown). However, the large amount of non-specific nuclear 
staining observed with this antibody precluded detection of cell body staining in 
Scn1b+/W and Scn1bW/W mice (data not shown) and explains why this was not reported 
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previously (Wimmer et al., 2015). Anti-1 staining observed in neuronal cell bodies in 
Scn1bW/W cortical neurons was layer specific. Figure 2.6 G-I shows limited cell body 
staining in layers II and VI. In contrast, a much higher proportion of β1-positive cell 
bodies were Ctip2-positive neurons in layer V (Figure 2.7, B, C, G, H), suggesting that 
1-C121W localization may be neuronal cell type specific. 
Taken together, our immunofluorescence and cell surface biotinylation results suggest 
that β1-C121W reaches the neuronal cell surface in vivo, but is not translocated to 
axonal subcellular domains and instead remains localized to neuronal soma.  
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Figure 2.7 β1-C121W is localized at the soma of layer V cortical neurons 
Representative confocal images of cortical layer V from Scn1b+/+ (A, B), Scn1b+/W (C, 
D), Scn1bW/W (E, F), Scn1b+/- (G, H), and Scn1b-/- (I, J) mice. The left panel for each 
genotype is a merged image of anti-Ctip2 (red), and anti-β1 (green) staining, and the 
following two panels show anti-β1 (white) followed by anti-Ctip2 (white) staining. 
Arrowheads indicate examples of β1-positive soma in Scn1b+/W and Scn1bW/W mice. 
Lower magnification images (A, C, E, G, I) show the layer specificity of 1-positive 
soma. Higher magnification images (B, D, F, H, J) showing Ctip2-positive layer V 
neurons are also presented. Scale bar (A, C, E, G, I): 100 μm. Scale bar (B, D, F, H, J): 
20m. Three mice of each genotype were tested.  
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Discussion 
The objective of this study was to determine the mechanism of how the SCN1B-C121W 
GEFS+ mutation alters VGSC β1 function in vivo. To address this question, we used a 
multi-disciplinary approach that included behavioral, biochemical, and 
immunofluorescence analysis of transgenic mouse models. We report that Scn1b+/W 
GEFS+ mice are more susceptible to thermally induced seizures than Scn1b+/- or 
Scn1b+/+ mice. Biochemically, 1-C121W polypeptides are expressed at lower levels 
than 1-WT in brain and migrate at a lower apparent molecular weight on SDS-PAGE 
gels. PNGase digestion followed by Western blot analysis shows that this molecular 
weight difference is likely due to incomplete glycosylation of the mutant 1 polypeptide 
in vivo. Surface biotinylation assays showed that 1-C121W polypeptides are 
expressed at the cell surface of cultured Scn1bW/W cortical neurons. 
Immunofluorescence confocal microscopy demonstrates that β1-C121W localizes to the 
neuronal cell body in Scn1bW/W brain sections, however, the subcellular localization of 
these mutant 1 subunits is limited to the soma and precluded from the axon. Our 
available model and tools do not allow us to distinguish between WT and mutant 1 
subunits by immunofluorescence in Scn1b+/W mice and thus to determine whether 
mutant 1 subunits also translocate to the axon in the presence of WT subunits. The 
observation that the level of anti-1 immunofluorescence at optic nerve nodes of 
Ranvier is higher in Scn1b+/W GEFS+ compared to Scn1b+/- mice may suggest that WT 
and mutant 1 subunits may be present together in axonal domains. Alternatively, 
however, the observation of a small, but significant, reduction in β1-positive AISs in 
layer II and VI Scn1b+/W sections compared to Scn1b+/+ and Scn1b+/- may suggest that 
85 
 
mutant  subunits may prevent a portion of WT  subunits from entering the axon.  
Finally, even though 1-C121W is expressed at the cell surface in Scn1bW/W neurons, 
its association with VGSC α subunits is disrupted as assessed by co-
immunoprecipitation.  
 
The crystal structure of the VGSC 1 Ig loop has not yet been solved.  However, 
important information can be gleaned from the crystal structure of a VGSC 4 Ig loop 
containing a C to W mutation at residue 131, corresponding to 1-C121W (Gilchrist et 
al., 2013). Importantly, introducing this mutation in the disulfide cysteine bridge of β4, 
which is conserved in all five VGSC  subunits, did not disrupt protein folding or plasma 
membrane trafficking compared to 4-WT as assessed in Xenopus oocytes. However, 
the C to W mutation did disrupt the ability of β4 to modulate sodium current expressed 
by Nav1.2 as well as result in potential alterations in β4 glycosylation (Gilchrist et al., 
2013), similar to our present results for 1-C121W. 
 
Our results, taken together with our previous data showing that 1-C121W cannot 
participate in trans homophilic cell-cell adhesion (Meadows et al., 2002), suggest that 
the SCN1B-C121W GEFS+ mutation confers a deleterious gain-of-function. We 
propose that in Scn1b+/W GEFS+ mice, non-functional 1-C121W subunits are 
expressed together with 1-WT subunits at the plasma membrane and thus effectively 
reduce the level of 1 function in neurons by diluting the density of WT subunits. 1-
mediated trans homophilic cell-cell adhesion may be particularly disrupted by this 
mechanism, as WT-mutant or mutant-mutant 1 subunit pairs may be aligned, but not 
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associate, in trans on adjacent axons, resulting in areas of aberrant adhesion and 
fasciculation. In addition, we propose that mutant 1B subunits, which are normally 
soluble ligands for cell adhesion (Patino et al., 2011), are co-secreted with WT 1B 
subunit in Scn1b+/W developing brain, yet are non-functional and effectively change the 
functionality of secreted WT 1B subunits. This scenario is different than in Scn1b+/- 
neurons, in which only WT 1 and 1B subunits are expressed. In Scn1bW/W mice, 
which model the severe epileptic encephalopathy Dravet syndrome (Wimmer et al., 
2010; Ogiwara et al., 2012) , all expressed 1 subunits are mutant and thus fail to 
associate with VGSC  subunits, fail to participate in cell-cell adhesion, and fail to 
translocate from the cell body to axonal subcellular domains.  Thus, we propose that, 
while mutant 1 subunits are expressed at the neuronal cell surface in Scn1bW/W mice, 
this model is functionally similar to Scn1b null mice, which also model Dravet syndrome 
(Patino et al., 2011).  
 
In our previous work we showed that covalent VGSC -β2 association, via formation of 
an extracellular disulfide bond, is required for β2, but not , subunit translocation to 
nodes of Ranvier (Chen et al., 2012). Our present results suggest that association with 
VGSC α subunits, although non-covalent (Hartshorne and Catterall, 1981), may be 
required for 1 translocation to axonal domains: We were unable to detect association 
between β1-C121W and VGSC α subunits and we did not detect β1-C121W at the AIS 
or nodes of Ranvier in Scn1bW/W mice. Thus, in a mechanism similar to 2 
association, 1 association through extracellular domains may be required for proper 
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 subunit localization in neurons. We have previously proposed that β1 and β4 have 
opposing actions on neuronal excitability with β1 acting as a ‘brake’ via promotion of 
VGSC inactivation (Aman et al., 2009). We showed that β1-C121W was unable to exert 
these modulatory effects (Aman et al., 2009). Our results here suggest that the absence 
of mutant β1 subunit association with VGSC  subunits may partially explain 
hyperexcitability in SCN1B-C121W-linked epilepsies.  
 
In addition to modulating VGSCs, 1 subunits are known to associate with voltage-
gated potassium channels that express A-type current in neurons (Marionneau et al., 
2012). An important future experiment will be to assess the effect of the SCN1B-C121W 
mutation on 1 association with Kv4.2 in Scn1bW/W brain. While we attempted these 
experiments, the solubilization conditions for immunoprecipitation of VGSCs and Kv4.2 
channels using available antibodies were incompatible. Thus we were unable to 
determine whether 1-C121W subunits maintain their association with Kv4.2. In the 
future, with higher quality antibodies, we may be able to assess whether aberrant 1-Kv 
association also contributes to the GEFS+ phenotype. 
 
Taken together, our studies provide evidence for a complex molecular mechanism 
leading to changes in excitability and thermal seizure susceptibility in Scn1b+/W GEFS+ 
mice compared to Scn1b+/- mice. Unlike other epilepsy-associated SCN1B mutations 
(Patino et al., 2009), SCN1B-C121W does not appear to cause intracellular retention 
and instead confers deleterious gain-of-function. Therefore, the mechanisms underlying 
SCN1B-linked epilepsy may be diverse, requiring the generation of specific animal 
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models of SCN1B epilepsy mutations to better understand β1 and β1B physiology. To 
date, 9 unique SCN1B mutations in epilepsy patients have been reported (O’Malley and 
Isom, 2015). Using transgenic mouse and human patient-derived induced pluripotent 
stem cell models and strategies similar to the present study, a better understanding of 
the affected molecular pathways may lead to the development of novel therapeutics for 
patients with SCN1B-linked epilepsy.  Moreover, because SCN1B epilepsy mutations 
are largely inherited, rather than de novo, effective genetic counseling strategies can be 
developed. 
CW vs. 
+/- 
 
p=0.0022 
CW vs. 
WT
 
p=0.0001 
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Chapter 3. New avenues of discovery for SCN1B-
C121W and β1 physiology 
My thesis work emphasizes the importance of studying sodium channels in their native 
environment in vivo, with endogenous levels of expression and native channelome 
components. However, there are many questions that need to be addressed in future 
work. Based on my work, which builds on the work of others, SCN1B-C121W could alter 
normal physiology through a number of possible mechanisms as follows: 
1. Disruption of β1/β1B-mediated homophilic cell adhesion. Heterologous 
expression studies have demonstrated that the C121W mutation disrupts 1-
mediated trans homophilic adhesion (Meadows et al., 2002). As depicted in 
Figure 3.1, there are a number of other possible configurations for β1 and β1-
C121W cell adhesive interactions in Scn1b+/W mice (or GEFS+ patients), 
including cis adhesion, which have not been explored 
2. Aberrant neurite outgrowth and neuronal pathfinding. My data suggest that there 
are increased levels of β1 localization at optic nerve nodes of Ranvier Scn1b+/W 
mice compared to Scn1b+/-. One possible explanation for this is that β1-WT can 
chaperone β1-C121W, as depicted in Figure 3.1 D, such that β1-C121W may be 
present in axonal subcellular domains such as the AIS, which are critical for b1-
mediated neurite outgrowth (Brackenbury et al., 2008). In this scenario, non-
functional 1-C121W subunits may dilute the density of 1-WT subunits at the 
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plasma membrane and thus effectively reduce the level of 1 function at the AIS. 
1-mediated trans homophilic cell-cell adhesion may be particularly disrupted in 
this mechanism, as WT-mutant or mutant-mutant 1 subunit pairs may be 
aligned in trans on adjacent axons, resulting in areas of aberrant fasciculation. 
3. Altered modulation of sodium and/or potassium current. My results show that β1-
C121W does not associate with VGSC α subunits in brain membranes. This 
absence of association may open the door, so to speak, for modulation of INa by 
other  subunits or other compensatory mechanisms. As discussed in Chapter 2, 
our available tools precluded the investigation of β1-C121W association with K+ 
channels, e.g. Kv4.2. Here, altered association would also be predicted to affect 
the excitation-inhibition balance. 
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Figure 3.1 Possible homophilic β1 associations in Scn1b+/W mice. 
All β1 trans- and cis-homophilic adhesion complexes which may occur in Scn1b+/W 
mice. Red circles indicate W121. A. β1-WT/β1-WT trans-homophilic adhesion is known 
to promote neurite outgrowth, as we have shown (Davis et al., 2004). B. It is unknown 
whether the β1-WT/β1-C121W trans-homophilic adhesion complex occurs, but this 
dimer could disrupt homophilic adhesion if β1-C121W is unable to stimulate the neurite 
outgrowth pathway. Similarly, complex d could make less β1-WT available to bind with 
VGSC α subunits, K+ channels, and cell adhesion partners. Complex C has been 
proposed, but it is difficult to show that this complex is present. If β1-C121W cis-dimers 
(E) or β1-C121W monomers (F) exist, our data suggests they do not bind VGSC α 
subunits. 
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Before discussing how each of these mechanisms might be tested, I would like to 
describe some of the available tools that could be used or developed to better answer 
these questions. 
A difficult challenge in studying Scn1b is differentiating the physiological effects of β1 
vs. β1B in vivo. In vitro, β1B has cell adhesive and channel specific VGSC α subunit 
modulatory functions, similar to β1 (Qin et al., 2003; Patino et al., 2011). However, the 
impact of these functions in vivo has yet to be explored. β1B in Scn1b-C121W mice also 
contains the C121W mutation and the role of β1B-C121W in SCN1B-C121W - 
associated epilepsy will also need to be investigated. This presents a complex, multi-
faceted problem. There is no one approach that can address all of the complexities. 
Despite several attempts, currently available β1B antibodies recognize human but not 
mouse β1B and thus cannot be used to study β1B in mouse models in vivo. The anti-
Scn1b antibodies used in my thesis, which we developed in collaboration with Cell 
Signaling Technology, are directed against extracellular or intracellular epitopes. To 
date, we have not observed differential staining patterns in mouse brain using these two 
antibodies. It is possible that β1 and β1B have identical sub-cellular localization patterns 
in brain. However, it is more likely that, because 1B is predominantly expressed in 
embryonic brain, the low levels of β1B protein in postnatal brain are undetectable. In a 
first attempt to address the functional roles of 1B, other members of our lab generated 
a BAC transgenic mouse expressing β1B, but not β1. When bred back onto the Scn1b-/- 
mice such that 1B but not 1 is expressed, mice have a phenotype that is 
indistinguishable from Scn1b-/- mice (paper in preparation). Therefore, β1B is not 
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sufficient to rescue Scn1b null epilepsy. It may be that the in vivo cell adhesive partner 
of 1B is 1 and thus expression of both gene products is essential for normal 
excitability. The next step will be to generate a β1B-specific knockout mouse line (that 
expresses 1 but not 1B) to further dissect the respective roles of each splice variant 
in normal physiology. One method by which splice-variant selective knockout mice have 
been successfully generated is to insert a preterm translational stop codon preceded by 
an ER-retention signal (KDEL) (Dours-Zimmermann and Zimmermann, 2012). In this 
study, placement of this sequence ablated synthesis of the splice variants containing 
the targeted exon, likely by KDEL-promoted intracellular degradation of the mutant 
fragment. To generate a β1B splice-variant specific knockout, we could insert a KDEL-
stop codon after the end of exon 3, but prior to the stop codon for β1B, as indicated in 
Figure 3.2. The biggest challenge with this type of transgenic mouse is that we would 
need to ensure that splicing of β1 mRNA and regulation of β1 expression are not 
disrupted. To accomplish this, we would need to use a combination of in situ 
hybridization, RT-PCR, and immunofluorescence throughout early development to 
ensure that β1 is still expressed in the same developmental manner as Scn1b+/+ mice. 
Another challenge of studying β1 subunits is antibody sensitivity. Although the current 
antibodies we have are specific for β1, their affinity is such that we can only detect β1 in 
vivo in subcellular locations where β1 density is high. To solve this issue, we are 
generating a C-terminal V5 epitope-tagged β1 mouse using a CRISPR/Cas strategy in 
collaboration with the University of Michigan Transgenic Core. Testing will be essential 
to ensure similar developmental expression patterns and functionality of β1-V5  
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Figure 3.2 Topology of Scn1b.  
The C121W mutation is located in exon 3, as indicated. ‡ indicates the proposed 
location for a premature translational stop codon preceded by an ER-retention signal 
(KDEL). This region is only included in β1B. 
 
compared to β1-WT. Furthermore, we would need to ensure that β1B expression is not 
disrupted. With this mouse in hand, we will again use a CRISPR/Cas strategy to insert 
epilepsy mutations, including SCN1B-C121W, into this mouse. Because anti-V5 
antibodies are very clean, have high sensitivity, and can be used for complex 
methodologies like immune-electron microscopy, this would allow us to understand 
SCN1B-linked epilepsy mutations in vivo with greater resolution and reliability. For 
example, we have shown evidence in vitro that β1 localizes to the axonal growth cone in 
cultured neurons (Brackenbury et al., 2008). Unfortunately, this cannot be detected in 
vivo, either because it does not occur or, more likely, because of insufficient antibody 
sensitivity. 
All future mouse models will need to be thoroughly tested to ensure similar temporal 
and spatial expression of β1 and β1B compared to Scn1b+/+ mice. Nevertheless, the 
advantages of studying sodium channel physiology in vivo are clear based on the cell-
type specificity of heterologous cell assay results and the fact that generation of 
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transgenic mouse models has become much less time-consuming and expensive. It is 
accepted in our field that heterologous cell lines cannot replicate the neuronal 
channelome. 
While mouse models have many advantages for studying epilepsy, mice are not small 
humans! Related GEFS+ patients with the same SCN1B mutation exhibit a wide variety 
of epileptic phenotypes (Table 1.2). This suggests that genetic background affects the 
epileptic phenotype. To account for this, we have generated human induced pluripotent 
stem cells (hiPSCs), derived from fibroblasts from a GEFS+ patient with p.C121W. This 
work was done in collaboration with Dr. Jack Parent and patient samples were provided 
by our collaborator, Dr. Ingrid Scheffer (Wallace et al., 1998). This powerful method 
allows us to study human GEFS+ neurons, with p.C121W in the presence of potential 
interacting proteins. We have previously used this technique in our laboratory, in a 
collaboration with Dr. Jack Parent and Dr. Miriam Meisler to study forebrain neurons 
derived from DS patients with SCN1A mutations (Liu et al., 2013). This approach will 
allow us to study the C121W mutation in native, human neurons in the presence of the 
patient’s genetic background. By using mouse models and iPSC-derived neurons, we 
can directly compare the mouse and human disease models and uncover possible 
species-or mouse strain-dependent effects. Our hope is that by comparing both models 
we can identify common pathogenic mechanisms that lead to GEFS+ as well as 
understand which specific classes of neurons are represented by the iPSC neuronal 
cultures. 
The models proposed above will help us address the following critical questions. 
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Does SCN1B-C121W disrupt β1/β1B homophilic interactions? 
The differences we observed in 1 vs. 1-C121W glycosylation may impact homophilic 
and heterophilic β1/β1B cell adhesion. The structure of the β1 Ig loop is very similar to 
that of myelin P0 (McCormick). Homophilic interactions of myelin P0 require 
glycosylation of the P0 pair (Filbin and Tennekoon, 1993). Thus, changes in β1 
glycosylation may underlie abrogation of β1-C121W/β1-C121W trans-homophilic 
interactions that we have previously reported (Malhotra et al., 2000; Meadows et al., 
2002). However, what has not been explored is the remaining possible combinations of 
β1-WT and β1-C121W that could have aberrant function. β1-C121W/β1-WT trans-or 
cis-homophilic adhesion complexes also could decrease the amount of β1-WT available 
to modulate neuronal pathfinding or associate and modulate sodium or potassium 
channels (Figure 3.1). For example, it is known that VGSC complexes are very tightly 
packed at the AIS and nodes of Ranvier. If β1-C121W associates in cis with β1-WT 
associated with VGSC α subunits (Figure 3.1 D), the slight conformational difference of 
the β1-C121W domain could disrupt the packing. Similarly, it is hypothesized that at 
points of cell-cell adhesion, such as paranodal domains, cell adhesion molecules are 
packed in a ‘zipper-like’ configuration, where molecules are in cis and trans 
configurations at the same time. Models suggest that this arrangement increases 
adhesion strength (Kunz et al., 2002). Therefore, if β1-C121W can associate in cis or 
trans with β1-WT, this tight adhesion pattern could be disrupted. 
The first step in understanding whether these mechanisms are occurring in Scn1b+/W 
mice is to determine whether β1-C121W and β1-WT associate in trans. We could assay 
this using two populations of Drosophila S2 cells: one transfected with EGFP and β1-
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C121W and the other transfected with RFP and β1-WT. If β1-C121W and β1-WT can 
associate in trans, mixing of the two cell lines would result in aggregates containing 
green and yellow fluorescence. In contrast, if 1-WT associates with itself but not with 
1-C121W, then cell aggregates will contain only red fluorescence and green 
fluorescent cells will remain in suspension. A caveat here is that the absence of mixed 
cell aggregation in this experiment would only eliminate the possibility of WT-mutant 
trans-homophilic adhesion and does not test the possibility of cis-homophilic adhesion 
between these two molecules (Figure 3.1 B vs. D). Next, we would need to determine 
where β1-C121W and 1-WT co-localize in Scn1b+/W mouse brain and are thus 
available to associate in vivo. My data show increased anti-β1 staining at the nodes of 
Ranvier in Scn1b+/W mice compared to Scn1b+/- mice. However, Scn1bW/W mice showed 
no specific anti-β1 staining at nodes. These data suggest that translocation to nodes 
β1-C121W may be facilitated by β1-WT in Scn1b+/W mice and that these two subunits 
may associate in cis. Alternatively, it is also possible that β1 localization at the nodes of 
Ranvier is upregulated in Scn1b+/W by some other compensatory mechanism not 
present in Scn1b+/- mice. Therefore, to distinguish these possibilities, we could use the 
proposed β1-C121W-V5 mice, and using the same method to generate β1-HA mice. By 
crossing these two lines we would generate mice which express β1-C121W-V5 and β1-
WT-HA. Similar to Figures 2.5 – 2.7, we could use immunohistochemistry to determine 
whether V5-tagged β1-C121W and HA-tagged β1-WT is present at AISs and nodes of 
Ranvier. We could also immunoprecipitate using a V5 antibody to specifically pull down 
β1-C121W-Fc and immunoblot for HA to determine whether β1-C121W associates with 
β1-WT in vivo. Together these experiments would help elucidate the effect of p.C121W 
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on β1 trans- and cis-homophilic adhesion, which would help interpret the results from 
electrophysiology and neurite outgrowth experiments. For example, if β1-C121W does 
not traffick to nodes of Ranvier or AISs, but does associate with β1-WT, then current or 
action potential changes are likely due to having less β1-WT available. 
Does Scn1b-C121W result in aberrant neurite outgrowth, neuronal 
pathfinding, or fasciculation defects? 
Scn1b deletion results in increased numbers of dentate granule cells (DGCs) and 
newborn DGCs in the hilus of the dentate gyrus at P5, prior to seizure onset and 
observation of spontaneous firing (Brackenbury et al., 2013). At P14,  
electrophysiological recordings show increased spontaneous firing and neuronal 
excitability in Scn1b-/- cortical and hippocampal slices compared to WT (Patino et al., 
2009) (Brackenbury et al., 2013). By this age, Scn1b null mice have defects in 
cerebellar granule neuron (CGN) migration and fasciculation, corticospinal tract (CST) 
pathfinding abnormalities, and increased proliferation of the external granular layer 
(EGL) of the cerebellum (Brackenbury et al., 2008). These developmental changes may 
be due in part to the loss of β1 trans-homophilic adhesion in Scn1b null mice, which is 
required for CGN β1-mediated neurite outgrowth (Davis et al., 2004). Based on these 
data, we have hypothesized that the developmental defects precede epileptiform activity 
(Brackenbury et al., 2013) and may contribute to the initiation of the seizure phenotype. 
This may be a common epileptogenic mechanism in epilepsies caused by SCN1B 
mutations. 
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Although β1-C121W is incapable of trans-homophilic adhesion in vitro (Meadows et al., 
2002), my data suggest that β1-C121W may confer a deleterious gain of function. As 
discussed above, β1-C121W may associate with and therefore alter localization of β1-
WT. Furthermore, it is unknown whether β1-C121W can associate with other known β1 
cell adhesion partners, e.g. neurofascin-186, contactin, NrCAM, N-cadherin, or 
tenascin-R. We have shown that β1-mediated neurite outgrowth requires contactin and 
Fyn kinase (Brackenbury et al., 2008). Therefore, I hypothesize that if we were to 
compare Scn1b+/W mice to Scn1b+/- and wildtype mice they may have different extents 
of defective neurite outgrowth, CGN migration and fasciculation, and CST pathfinding 
and fasciculation. It would be interesting to also determine whether neurite outgrowth is 
defective in iPSC-derived GEFS+ patient neurons compared to controls in culture. 
Finally, it may be possible to inject EGFP-labeled GEFS+ or control patient iPSC-
derived neurons into the developing mouse brain and compare migration and degree of 
neuronal arborization in situ. 
To test this I would use our previously established methods to investigate whether 
Scn1b+/W mice have aberrant neuronal migration, proliferation, and/or neuronal 
pathfinding compared to Scn1b+/- mice (Brackenbury et al., 2008, 2013). As we have 
done previously (Brackenbury et al., 2013), I would stain sections from P5 hippocampus 
of Scn1b+/W mice to determine whether the migration and proliferation of neuronal 
subtypes are altered. Newborn dentate granule cells (DGCs), interphase (proliferating) 
cells, and DGCs can be identified using Prox1, Ki67, and Nissl respectively. Nissl 
staining will identify whether there is a decrease in cell density in the dentate gyrus, as 
we see in Scn1b-/- mice. If differences are seen, then we can investigate whether there 
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are increased Ki67 positive proliferating cells and/or increased post-mitotic dentate 
granule cells, labeled by Prox1, in the hilus. This could indicate altered regulation of 
proliferation in the hilus and defective migration of the dentate granule cells. Differences 
in neuronal migration could lead to changes in network excitability. In Scn1b-/- mice we 
found that some of the aberrant neurons in the dentate gyrus were parvalbumin-positive 
GABAergic interneurons (Brackenbury et al., 2013). Prox1-positive hilar ectopic DGCs 
are known to arise from progenitors following status epilepticus (Kron et al., 2010), but 
can also be seen prior to seizure onset (Brackenbury et al., 2013). Therefore, there may 
be a minimum level of spontaneous activity required, or a particular pathway that needs 
to be hyperexcitable, for the appearance of ectopic DGCs. If Scn1b+/W mice have less 
spontaneous activity or different active pathways, we may not see this change. 
To determine if p.C121W affects β1-mediated neurite outgrowth, we could use our 
previously established assay (Davis et al., 2004; Brackenbury et al., 2008). Briefly, 
acutely dissociated CGNs or iPSC-derived neural progenitors are plated on a 
monolayer of Chinese hamster lung (CHL) 1610 cells ± expression of β1. Cultures are 
grown in the absence of FGF, to prevent FGF-dependent neurite outgrowth, which is 
independent of 1-mediated neurite outgrowth in CGNs (Brackenbury et al., 2008). 
Using WT littermates and Scn1b-/- mice as positive and negative controls, respectively, 
we then fix the cells 24 hours after culture, stained for Tuj1 (a neuronal β-tubulin), and 
imaged using confocal microscopy. The longest neurite for each neuron is measured, 
as previously described (Davis et al., 2004). By combining 1610 cells expressing β1 
with Scn1bW/W neurons and 1610 cells expressing β1-C121W with Scn1b+/+ neurons, 
we can determine whether β1-C121W can interact trans-homophilically with β1-WT to 
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stimulate neurite outgrowth. It is possible that when β1-WT is expressed in the neuron, 
it may still be able to induce neurite outgrowth in response to β1-C121W adhesion, but 
the reverse may not be true because β1-C121W may be incapable of inducing 
intracellular signal transduction. In this way, we could specifically test the functional 
output of β1-C121W/β1-WT trans-homophilic cell adhesion, if it occurs. 
Regarding injection of GFP-labeled patient-derived iPSC-derived neurons into 
developing WT or GEFS+ mouse brain, brain slices could be stained for Tuj1 (to 
indicate neurons), and MAP2 (which will not stain axons). GFP-positive neurons would 
then be imaged using confocal microscopy with the resulting images re-constructed in 
three-dimensions. We could compare neuronal branching complexity using Scholl 
analysis, total neurite length, longest neurite length, and axonal length of iPSC neurons 
vs. the surrounding mouse neurons. If the brain region the neuron ends up in seems to 
affect neurite outgrowth, we could transplant patient and control iPSC-derived neurons 
with different fluorescent markers and inject them both into the same brain. Then we 
could select matched pairs of control and patient neurons to compare. This may be 
particularly important when injecting into Scn1b null animals, to control for differences in 
seizure activity(Brackenbury et al., 2013)(Brackenbury et al., 2013) . Both of these 
approaches would allow us to examine the effect of SCN1B-C121W on iPSC-derived 
GEFS+ patient neurite outgrowth. 
Finally, we could also examine changes in fasciculation of the CST. Scn1b-/- mice have 
significant CST fasciculation and pathfinding abnormalities (Brackenbury et al., 2008). 
We have observed these defects by implanting a DiI crystal into one side of the primary 
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motor cortex in P9-10 mice. Six days after surgery, we anesthetized and fixed the brain 
and spinal cord of the same mice. Brain and spinal cord sections were then examined 
and scored for various types of defasciculations, as described previously (Brackenbury 
et al., 2008). 
We anticipate that mice expressing β1-C121W will have neuronal migration defects, 
similar, or less severe than Scn1b-/- mice, with Scn1b+/W mice having a milder (or 
absence) of some phenotypes compared to the Scn1bW/W  mice, which are expected to 
be similar to Scn1b-/- mice. Overall, we anticipate that p.C121W expression will result in 
an increase in proliferating and Prox1+ DGCs in the hilus of the DG, accompanied by an 
overall dispersion of DGCs in the GCL (seen as a decrease in the density of Nissl+ 
DGCs in the GCL and an increase in the thickness of the GCL). Finally we expect to 
see some abberant CST fasciculation, although not as dramatic as that observed in null 
mice. Collectively, these data will determine the effect of p.C121W on neuronal 
development. 
It may be that we will see no differences in neuronal migration, proliferation, or neurite 
extension in Scn1b+/W mice or GEFS+ patient-derived iPSC neurons. This would 
suggest that p.C121W expression does not result in changes in neuronal migration or 
overall brain morphology, and that the GEFS+ phenotype stems mainly from changes in 
neuronal excitability at the cellular level. However, it could also be the case that β1 
mediates migration of other key populations of neurons, such as other sub-populations 
of interneurons, pyramidal cells, and basket cells, and we may detect variations there. 
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How does p.C121W affect sodium and potassium channel function 
and neuronal excitability in mice compared to patient neurons? 
Our data suggest that β1-C121W does not associate with VGSC α subunits. However, 
preliminary data collected by Dr. Luis Lopez-Santiago in our laboratory, indicate that 
SCN1B+/W hiPSC-derived neurons have increased INa density compared to controls 
(mean ± SE, -167 ± 31 pA/pF; -72.9 ± 5.2 pA/pF). The peak sodium current from the I-V 
curve was similarly increased (mean ± SE, -177 ± 31 pA/pF; -86.7 ± 9.6 pA/pF). This 
could be due to compensatory upregulation of sodium channels. We reported a similar 
result in iPSC-derived DS patient neurons (Liu et al., 2013). β1 also associates with and 
modulates Kv4.2  in vivo (Marionneau et al., 2012). In this study, Kv4.2 was 
immunoprecipitated from 40 mg of wild-type or Kv4.2-/- mouse brain protein. Mass 
spectroscopy proteomic analysis detected a β1 peptide in wild-type but not Kv4.2-/- 
samples. In addition, heterologously-expressed Kv4.2 was shown to associate with β1-
EYFP, detected using anti-YFP antibody (Marionneau et al., 2012). Following shRNA 
knockdown of Scn1b in this heterologous system, A-type current, the majority of which 
is mediated by Kv4.2, was specifically decreased in amplitude (Marionneau et al., 2012). 
As discussed in chapter 1, β1 has been shown to modulate Kv1 and Kv3 channels in 
heterologous overexpression systems in vitro. Thus, p.C121W expression may result in 
altered potassium and/or sodium current in vivo through altered β1 modulation or other 
compensatory mechanisms. Overall, this could contribute to an altered balance 
between excitation and inhibition leading to increased seizure susceptibility. 
I tested whether β1-C121W could co-immunoprecipitate with Kv4.2. I tried two different 
anti-Kv4.2 antibodies from NeuroMab (K57 and L28) that were recommended by our 
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collaborator, Dr. Jeanne Nerbonne, whose group performed the initial Kv4.2-β1 
coimmunoprecipitation (Marionneau et al., 2012). The L28, but not the K57, antibody 
gave a consistent immunoreactive signal on a control Western blot. Because L28 is not 
rated by NeuroMab for immunoprecipitation, I decided to immunoprecipitate using anti-
β1 and immunoblot for Kv4.2 using the L28 antibody. Using an anti-1 antibody targeted 
against an intracellular β1 epitope (Cell Signaling Technologies), I optimized β1 
pulldown by testing different dilution buffers. In order to get clean immunoprecipitation of 
β1, I had to add either CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate) detergent or β-octyl glucoside to the dilution buffer. Without the 
addition of one of these detergents, there was very little β1 protein detected in the 
immunoprecipitated samples. However, even with optimized β1 immunoprecipitation, 
there was no Kv4.2 signal observed in wild-type brain membrane proteins. After further 
discussion with Dr. Nerbonne, we decided that 1-Kv4.2 association may not be strong 
enough to detect biochemically. However, this does not mean that β1 modulation of 
Kv4.2 does not have physiological relevance. Measuring K+ currents, especially A-type 
current, in Scn1b+/W and Scn1bW/W mice may inform the mechanism of increased 
seizure susceptibility. Using the β1-V5 mice that are in progress, we could easily detect 
or coimmunoprecipitate even small levels of β1, due to the high affinity of V5 antibodies. 
This would make detecting an association between Kv4.2 and β1-C121W more feasible. 
If electrophysiological studies suggested β1-C121W modulation of A-type K+ current, it 
would also be reasonable to try to immunoprecipitate Kv4.2 from Scn1bW/W mice and 
use mass spectroscopy to detect β1-C121W as in (Marionneau et al., 2012).  
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In future experiments, it will be critical to verify our preliminary hiPSC neuron results and 
determine the mechanism of increased sodium current. In addition, it will be important to 
determine which neuronal population has these properties in Scn1b+/W mice. This would 
require a complex computational neuroscience approach involving electrophysiology 
and modeling to analyze changes in current and network excitability. The knowledge 
gained from these experiments would help identify the mechanism(s) by which 
p.C121W alters β1 function(s), and how this affects VGSC function and neuronal 
excitability. 
While research of some misfolded-protein diseases, including cystic fibrosis, has 
prompted the development of chaperone protein therapies, my proposed mechanism 
suggests that this may not be an effective approach for SCN1B-C121W –linked 
epilepsy. β1-C121W is expressed at the cell surface, and therefore does not need a 
chaperone protein to assist in trafficking to the cell surface. Rather, the problem seems 
to lie in the incomplete glycosylation and misfolding of β1-C121W. Furthermore, the 
evidence from Scn1b+/- mice suggests that the increased seizure susceptibility of 
Scn1b+/W mice is not due to lower β1 expression. Therefore, based on the data 
presented here, a potential treatment to target and remove the detrimental β1-C121W 
may ameliorate some of the detrimental effects of the mutant protein. This would need 
to be done without significant toxicity to the neurons and other cells containing β1-
C121W. One possible approach would be to use recently developed “ubiquibodies” 
(Portnoff et al., 2014). These are targeted ubiquitin ligases linked to an antibody against 
a protein of interest. Portnoff et al. have shown specific targeting and depletion of an 
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otherwise stable protein in vitro. These “ubiquibodies” would need further development 
to test efficacy in vivo and in the central nervous system and a β1-C121W-specific 
antibody would need to be developed, which would be challenging considering the 
difficulty creating β1-specific antibodies. However, a β1-C121W-targeted “ubiquibody” 
could provide a means of removing the deleterious β1-C121W protein from the system. 
Further functional testing of sodium and potassium currents in vivo in Scn1b-C121W  
mice and in SCN1B-C121W patient-derived iPSCs could also reveal further insights into 
which anti-epileptic therapeutics might be most effective for this set of patients. 
Overall, as with many scientific pursuits, we are left with many questions and a few 
answers. The data I have presented here suggest that Scn1b-C121W confers a 
deleterious gain-of-function. β1-C121W localizes to the neuronal cell surface but does 
not associate with VGSC α subunits and does not localize to axon initial segments or 
nodes of Ranvier. Our previous results showed that, in addition to what I have found, 
β1-C121W does not participate in trans homophilic adhesion. Therefore, we have 
proposed that the increased seizure susceptibility observed in Scn1b+/W mice compared 
to Scn1b+/- mice may be explained by disrupted hemophilic cell adhesive interactions 
resulting in altered neuronal migration and pathfinding, as well as altered sodium and/or 
potassium current modulation. Further investigation of these mechanisms will help us to 
understand SCN1B-linked epilepsies and hopefully identify potential pathways for 
developing better therapeutic targets. 
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